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Lysosomal destabilization in retinal pigment epithelial cells activates the NLRP3 
inflammasome and induces IL-1β secretion 
 
ABSTRACT 
Age-related macular degeneration (AMD) is a leading cause of visual impairment and 
blindness, affecting over 30 million people worldwide. It is characterized by the appearance of 
insoluble deposits known as drusen in the outer retina, between the retinal pigment epithelium 
(RPE) and Bruch’s membrane. Drusen are heterogeneously composed of many compounds, 
including cholesterol, amyloid-β, and complement proteins. AMD also involves the accumulation 
of pigments collectively termed lipofuscin in RPE lysosomes. The underlying causes of AMD are 
unknown, but studies have implicated inflammatory processes in its pathogenesis. 
The NLRP3 inflammasome is a multiprotein complex, consisting of NLRP3, ASC, and 
caspase-1, that plays an important role in inflammation. Inflammasome assembly activates 
caspase-1 via proteolysis of its precursor, procaspase-1. Caspase-1 mediates the maturation of 
inflammatory cytokines such as IL-1β, as well as a form of cell death called pyroptosis. A myriad 
of chemically diverse agonists are known to activate the NLRP3 inflammasome, including 
insoluble particles and crystals, which destabilize phagolysosomes following internalization. As 
lysosomes are disrupted by the phagocytosis of certain drusen components, such as amyloid-β, 
or the detergent-like effects of the lipofuscin constituent A2E, I sought to evaluate the 
hypothesis that the destabilization of RPE lysosomes activates the NLRP3 inflammasome. 
Immunohistochemistry of human outer retinal sections revealed that NLRP3 was 
expressed in the RPE of AMD-affected eyes, but was not detectable in age-matched control 
retinas. The NLRP3 inflammasome components NLRP3, ASC, and procaspase-1 were 
expressed in the human RPE cell line ARPE-19 and in primary human RPE cells. Expression of 
 iv 
the IL-1β precursor, pro-IL-1β, in RPE cells was induced by treatment with NF-κB agonists such 
as IL-1α. Disruption of RPE lysosomes using the lysosomotropic agent L-leucyl-L-leucine methyl 
ester induced inflammasome activation, as evidenced by caspase-1 activation, processing and 
release of IL-1β, and pyroptotic cell death. These results suggest a mechanism of AMD 
pathogenesis in which molecular changes associated with AMD lead to lysosomal damage, 
activating the NLRP3 inflammasome in RPE cells and mediating vision loss by inducing IL-1β 
production and cell death. Therefore, the NLRP3 inflammasome may be a key mediator of AMD 
pathology and a potential target for therapeutic intervention. 
 v 
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GENERAL INTRODUCTION 
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PREFACE 
In this chapter, Figure 1 has been adapted with permission from the article, “Age-related 
macular degeneration and the extracellular matrix,” by L.V. Johnson and D.H. Anderson in The 
New England Journal of Medicine, July 22, 2004, Vol. 351, No. 4, pages 320-322, the copyright 
of which is held by the Massachusetts Medical Society. Figure 2 has been adapted with 
permission from the article, “NLRP3 inflammasome activation in retinal pigment epithelial cells 
by lysosomal destabilization: implications for age-related macular degeneration,” by W.A. 
Tseng, T. Thein, K. Kinnunen, K. Lashkari, M.S. Gregory, P.A. D’Amore, and B.R. Ksander in 
Investigative Ophthalmology & Visual Science, January 2013, Vol. 54, No. 1, pages 110-120, 
the copyright of which is held by The Association for Research in Vision and Ophthalmology, 
Inc.
 3 
INTRODUCTION 
 
Age-related macular degeneration (AMD) is the leading cause of vision loss in 
individuals of 50 years of age and over in industrialized nations and impairs the vision of more 
than 30 million people globally (Ambati et al., 2013; Cangemi, 2007; Coleman et al., 2008; Hu et 
al., 2013; Khandhadia et al., 2012; Parmeggiani et al., 2012). In the United States, roughly 15 
million people have AMD, with over 1.7 million individuals suffering from an advanced form of 
the disease (Friedman et al., 2004; Gryziewicz, 2005). As the average age of the American 
population increases, it is projected that three million people in the United States will have 
advanced AMD by the year 2020 (Friedman et al., 2004). 
AMD is characterized by pathological changes to the cells and structures of the outer 
retina, resulting in damage to the central region of the retina known as the macula. The macula 
contains the fovea and foveola, areas rich in cone photoreceptors, and is responsible for the 
high acuity central vision that is critical for activities such as reading, driving, and facial 
recognition (Ambati et al., 2013). Deterioration of central vision from AMD, therefore, has a 
severely adverse impact on quality of life. However, despite intensive research, the underlying 
etiology of AMD remains unknown (Liu et al., 2013). 
AMD can occur in two forms, often referred to as “dry” and “wet.” Dry AMD, also called 
atrophic or non-exudative AMD, accounts for over 85% of all AMD and is responsible for 10% of 
all vision loss associated with AMD. Dry AMD develops slowly over many years and can go 
undetected in its early stages (Bhutto and Lutty, 2012; Buschini et al., 2011). Its hallmark 
feature is the presence of yellow-to-white deposits known as “drusen” (German for “geode”) 
between the basal surface of the retinal pigment epithelium (RPE) and the multilayered 
extracellular matrix known as Bruch’s membrane (BrM) (Figure 1) (de Jong, 2006; Luibl et al., 
2006). Dry AMD is also associated with a thinning or atrophy of the RPE (Penfold et al., 2001). 
The RPE is responsible for supporting the survival and function of photoreceptors, which lie on  
 4 
 
Figure 1. Diagram of the outer retina with drusen accumulation. AMD involves pathological 
changes in the outer retina, consisting of light-sensing photoreceptors and the RPE. RPE cells 
maintain the health and function of the receptors, which lie on the apical surface of the RPE. 
The outer retina is nourished by blood flow from the vascular bed known as the choroid and its 
associated capillary layer, the choriocapillaris. Between the basal surface of the RPE and the 
choroid lies BrM, a multilayered extracellular matrix. In aging eyes, deposits referred to as 
drusen frequently accumulate between the basal lamina of the RPE and the inner collagenous 
layer of BrM. Drusen are the hallmark feature of AMD and are correlated with AMD progression. 
In dry AMD, RPE cells degenerate, resulting in the death of the photoreceptors they maintain, 
causing vision loss. In wet AMD, new blood vessels grow from the choroid, break through BrM, 
and invade the sub-RPE or subretinal space. Leakage of fluid from these nascent vessels 
causes vision loss. Reproduced with permission from New England Journal of Medicine 351(4): 
320-322. Copyright © 2004 Massachusetts Medical Society. 
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the apical side of the RPE (Bhutto and Lutty, 2012). When dry AMD progresses to its advanced 
form, called geographic atrophy (GA), patch-like regions of RPE cells deteriorate in the macula, 
leading to the death of the photoreceptor cells that they maintain (Anderson et al., 2013). As 
these patches grow and become confluent, they result in central scotomas, areas of vision loss 
in the center of one’s field of view (Ambati and Fowler, 2012; Wang et al., 2009). Despite 
extensive efforts, there are currently no available treatment options for dry AMD (An et al., 
2006). It is likely that the identification of key molecules involved in the pathogenesis of GA will 
be required for the development of therapeutics effective against this form of AMD. 
Wet AMD, also called neovascular or exudative AMD, is an advanced form of AMD that 
involves choroidal neovascularization (CNV). CNV is characterized by the growth of blood 
vessels from the choroid, the vascular bed that supplies the outer retina with oxygen and 
nutrients, and its capillary layer, the choriocapillaris (CC). The nascent vessels penetrate BrM 
and invade the sub-RPE or subretinal space (Campochiaro, 2013), and because they are highly 
permeable, these vessels leak fluid that can distort vision or cause detachment of the retina (de 
Jong, 2006). Wet AMD can progress very rapidly, potentially causing blindness within a matter 
of months (Munk et al., 2012). Although wet AMD accounts for a minority of total AMD, it is 
responsible for approximately 90% of severe vision loss caused by AMD (Donoso et al., 2006). 
Treatments are available for patients with neovascular AMD, primarily in the form of anti-
angiogenic agents that target vascular endothelial growth factor (VEGF) and are injected 
intravitreally (Miller, 2010). These treatments are often able to slow or halt vision loss caused by 
neovascular AMD, and in some cases can lead to limited recovery of visual acuity (Fong and 
Lai, 2013). However, not all patients with neovascular AMD respond to anti-VEGF therapy. 
Nevertheless, even though anti-VEGF agents are far from a cure for neovascular AMD, they 
can provide substantial improvements in quality of life for many patients. 
Over the past several years, an increasing body of evidence has accumulated that 
implicates a role for inflammation in the pathogenesis of both wet and dry AMD. For example, 
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many molecules present in drusen participate in inflammation (Hageman et al., 2001). Arguably, 
the most compelling evidence for an inflammatory contribution to AMD is the fact that AMD 
susceptibility is strongly associated with single-nucleotide polymorphisms (SNPs) in 
complement factor H, a major regulator of complement-mediated immune responses and 
inflammation (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 
2005). It is also becoming apparent that an inflammatory state called “para-inflammation,” which 
is milder in intensity than frank inflammation, participates in the development of AMD (Buschini 
et al., 2011; Medzhitov, 2008; Xu et al., 2009). 
Recent studies have implicated a molecular platform known as the NLRP3 
inflammasome in AMD pathogenesis. Inflammasomes are multiprotein complexes that mediate 
the processing of the inflammatory cytokines interleukin (IL)-1β and IL-18 into their mature, 
biologically active forms. The assembly and activation of inflammasomes is induced by stimuli 
that are often microbial products or associated with cellular damage, such as extracellular 
adenosine triphosphate (ATP), monosodium urate (MSU), and hyaluronan (Martinon et al., 
2006; Yamasaki et al., 2009). Accordingly, inflammasomes play a key role in innate immunity by 
mediating host defense against microbes as well as tissue and wound repair (Davis et al., 2011; 
Dupaul-Chicoine et al., 2010; Franchi et al., 2010; Thomas et al., 2009). However, excessive or 
uncontrolled NLRP3 inflammasome activity leads to a variety of inflammation-mediated 
diseases. Evidence indicates that the NLRP3 inflammasome is involved in Alzheimer’s disease, 
atherosclerosis, and type 2 diabetes (Duewell et al., 2010; Halle et al., 2008; Masters et al., 
2010; Rajamaki et al., 2010). Several recent studies using animal models have implicated the 
NLRP3 inflammasome in the development of AMD, but work in this area is early and there are 
even conflicting reports about whether the inflammasome is protective against AMD or 
contributes to its development (Doyle et al., 2012; Liu et al., 2013; Marneros, 2013; Tarallo et 
al., 2012). It is clear that a more complete understanding of inflammasomes, and the NLRP3 
inflammasome in particular, is essential for elucidating the etiology and pathogenesis of AMD. 
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Inflammasomes control caspase-1 activation 
 
Inflammasomes are multiprotein complexes that activate caspase-1, originally known as 
the IL-1β-converting enzyme (Martinon et al., 2002). Like all caspases, caspase-1 is a cysteine 
protease that cleaves peptide bonds following aspartate residues and is synthesized as an 
inactive enzyme precursor or zymogen (Lamkanfi and Dixit, 2012). The best-characterized 
substrates of caspase-1 are the cytosolic precursors of IL-1β and IL-18, referred to as pro-IL-1β 
and pro-IL-18, respectively (Brydges et al., 2013). Cleavage of pro-IL-1β or pro-IL-18 by 
caspase-1 generates the corresponding mature, biologically active cytokine, which is then 
released through an unconventional and incompletely understood secretory pathway (Lopez-
Castejon and Brough, 2011). Because of its role in inflammatory cytokine processing, caspase-
1 is categorized as an inflammatory caspase, as opposed to an apoptotic caspase. 
The inflammatory caspases are caspase-1, -4, -5, and -12 in humans and caspase-1,  
-11 and -12 in mice (Khare et al., 2010). Human caspase-4 and -5 are orthologous to murine 
caspase-11, and are believed to be the products of duplication in the caspase-11 gene (Bian et 
al., 2011). Although caspase-1 is not known to play a role in apoptosis, it mediates a distinct 
form of programmed cell death called pyroptosis that is independent of the activity of apoptotic 
caspases such as caspase-3 and -7 (Lamkanfi and Dixit, 2010). Whereas apoptosis preserves 
the integrity of the plasma membrane, pyroptosis involves the formation of pores in the plasma 
membrane that result in cellular swelling, lytic cell death, and release of cellular contents (Fink 
and Cookson, 2006). Thus, whereas apoptotic blebs can be cleared in an “immunologically 
silent” manner, pyroptosis is inherently proinflammatory (Lamkanfi and Dixit, 2010; Miao et al., 
2010a). Both apoptosis and pyroptosis induce DNA fragmentation, but via different mechanisms 
(Bergsbaken et al., 2009). By regulating caspase-1 activation, inflammasomes are key 
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regulators of IL-1β and IL-18 maturation, as well as pyroptosis. 
Inflammasome assembly is controlled by scaffolding proteins. Most known 
inflammasome scaffolding proteins are members of the nucleotide-binding domain, leucine-rich 
repeat-containing protein (NLR) family. The best-characterized inflammasome scaffolds are 
NLRP1, NLRP3, and NLRC4, as well as the non-NLR family protein absent in melanoma 2 
(AIM2), which belongs to the PYHIN family (Rathinam et al., 2012a). NLRs are a class of 
pattern recognition receptors (PRRs), which allow the innate immune system to detect 
pathogens, regardless of prior exposure, and to respond to cellular stress or injury (Kanneganti, 
2010). To do this, PRRs bind to common microbial motifs known as pathogen-associated 
molecular patterns (PAMPs) as well as to certain molecules released from injured or dying cells, 
such as ATP, called danger signals or damage-associated molecular patterns (DAMPs) 
(Schroder and Tschopp, 2010). PRRs may reside on the cell surface or in the cytoplasm; Toll-
like receptors (TLRs) are membrane-associated PRRs, whereas NLRs reside in the cytosol 
(Bauernfeind et al., 2011a). Each inflammasome scaffolding protein responds to certain sets of 
PAMPs and/or DAMPs. Inflammasomes are referred to by the name of their scaffolding protein, 
and the domain architectures of the different scaffolding proteins influence the compositions of 
the inflammasomes they assemble. 
All inflammasome scaffolding proteins contain at least one effector domain, typically at 
the N-terminus, that allows them to directly or indirectly recruit procaspase-1, the zymogen 
precursor of caspase-1. This effector domain is either a pyrin domain or a caspase recruitment 
domain (CARD) (Davis et al., 2011). These domains undergo homotypic association; pyrin 
domains bind other pyrin domains, and CARDs bind other CARDs. Procaspase-1 possesses a 
CARD, so scaffolding proteins that also have a CARD, such as NLRP1 and NLRC4, can directly 
bind procaspase-1 (Latz et al., 2013). Inflammasome scaffolds that lack a CARD, like NLRP3 
and AIM2, have a pyrin domain instead. This domain allows them to interact with an adaptor 
protein, apoptosis-associated speck-like protein containing a CARD (ASC), which has both a 
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pyrin domain and a CARD. Thus, scaffolds with a pyrin domain can recruit procaspase-1 
indirectly via ASC (Schroder and Tschopp, 2010). 
Recruitment of procaspase-1 to the inflammasome results in a high local concentration 
of the zymogen, which is believed to trigger proximity-induced autoproteolysis, generating active 
caspase-1 (Broz et al., 2010; Yang et al., 1998). The first step of the proteolytic conversion is 
the cleavage of procaspase-1 into a p35 fragment, which contains the CARD, and a p10 
subunit. Next, the p35 fragment is cleaved to yield the CARD and a p20 subunit (Broz et al., 
2010). Active caspase-1 is a tetramer comprised of two p20 subunits and two p10 subunits 
(Mao et al., 1998). Although NLRP1 and NLRC4 can each recruit procaspase-1 independently 
of ASC via their CARDs, the presence of ASC in these inflammasomes substantially improves 
caspase-1 activation and processing of IL-1β and IL-18. Addition of ASC to reconstituted 
NLRP1 inflammasome complexes increases caspase-1 activity by over two-fold (Faustin et al., 
2007), and ASC-deficient macrophages produce roughly 50% lower levels of IL-1β upon 
induction of the NLRC4 inflammasome, compared to wild-type (Miao et al., 2006). However, the 
mechanism through which ASC interacts with these inflammasomes remains unclear. Following 
the convention developed by Ting and colleagues, NLRs are named according to their N-
terminal effector domain (Ting et al., 2008). NLRs with an N-terminal pyrin domain are 
designated “NLRP,” whereas NLRs with an N-terminal CARD are referred to as “NLRC.” Human 
NLRP1 has both a N-terminal pyrin domain and a C-terminal CARD, but is named based on its 
N-terminal domain. 
Once caspase-1 has been activated, it can cleave the IL-1β and IL-18 precursors to 
produce mature IL-1β and IL-18. Because pro-IL-1β and pro-IL-18 lack signal peptides that 
would target them to the ER-Golgi secretory pathway, they reside in the cytosol. After 
processing, release of the mature cytokines occurs through an unconventional secretory 
pathway that remains poorly understood (Eder, 2009). Although cell membrane disruption and 
leakage of cytosolic contents due to pyroptosis has been considered as a possible mechanism, 
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the cytoprotective agent glycine inhibits inflammasome-mediated cell lysis and leakage but does 
not affect the release of IL-1β (Edgeworth et al., 2002; Qu et al., 2007; Verhoef et al., 2004), 
indicating that loss of membrane integrity is not a requirement for IL-1β release. Microvesicle 
shedding, secretory lysosome exocytosis, exosome exocytosis, and transmembrane ATP-
binding cassette transporters have all been proposed as mechanisms for IL-1β secretion (Eder, 
2009; Lopez-Castejon and Brough, 2011). Intriguingly, caspase-1 has been found to bind pro-
IL-1α and FGF-2, both of which lack consensus signal peptides, and facilitate their 
unconventional secretion (Keller et al., 2008). Although neither pro-IL-1α nor FGF-2 is a 
proteolytic substrate of caspase-1, the enzymatic activity of caspase-1 is required for their 
secretion, as either deletion of caspase-1 or treatment with caspase-1 inhibitors abrogates their 
release. These results indicate that caspase-1 mediates the unconventional secretion of certain 
proteins and suggest that IL-1β and IL-18 may rely on caspase-1 not only for their processing, 
but also their release. 
Although caspase-1 is the predominant enzyme that processes IL-1β and IL-18, other 
enzymes can also cleave pro-IL-1β and pro-IL-18 at positions sufficiently close to the site 
cleaved by caspase-1 and generate bioactive cytokine. Production of IL-1β by neutrophils in 
response to Pseudomonas aeruginosa infection is independent of caspase-1 and 
inflammasomes and instead relies on serine proteases (Karmakar et al., 2012). Additionally, IL-
1β production in a mouse model of necrotizing crescentic glomerulonephritis is substantially 
reduced in the absence of the neutrophil serine proteases proteinase 3 and neutrophil elastase 
(Schreiber et al., 2012). Furthermore, treatment of murine dendritic cells with the proapoptotic 
chemotherapeutic agents doxorubicin and staurosporine induces caspase-8-mediated IL-1β 
processing and release independently of caspase-1 (Antonopoulos et al., 2013). Thus, 
production of mature IL-1β does not necessarily mean that caspase-1 has been activated. 
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Activation and regulation of inflammasomes 
 
The regulation of inflammasome activity involves a “two-signal” mechanism. One signal 
induces the expression of pro-IL-1β, and the other signal triggers the assembly of the 
inflammasome via a scaffolding protein, resulting in the proteolytic activation of caspase-1 (Latz 
et al., 2013). As described above, each inflammasome scaffold is activated by particular PAMPs 
and/or DAMPs. NLRP1 is induced by muramyl dipeptide (MDP), a component of bacterial 
peptidoglycan (Faustin et al., 2007). In addition, certain variants of murine NLRP1b, one of the 
three NLRP1 paralogues in mice, recognize the Bacillus anthracis lethal toxin (Boyden and 
Dietrich, 2006; Franchi et al., 2012; Terra et al., 2010). NLRC4 is activated by flagellin and 
certain components of bacterial secretion systems (Zhao et al., 2011). Double-stranded DNA 
(dsDNA) triggers AIM2 (Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et 
al., 2009; Roberts et al., 2009), whereas NLRP3 responds to a diverse array of PAMPs and 
DAMPs (Bauernfeind et al., 2011a; Duewell et al., 2010). However, in order for an activated 
inflammasome to produce mature IL-1β, another signal must first induce pro-IL-1β expression, a 
process referred to as “priming” (Hornung and Latz, 2010). Because NF-κB regulates pro-IL-1β 
expression via a NF-κB-responsive element in the IL1B promoter, priming can be accomplished 
by NF-κB agonists such as the TLR4 ligand lipopolysaccharide (LPS), tumor necrosis factor α 
(TNFα), and the cytokine IL-1α (Eisenbarth et al., 2008; Hiscott et al., 1993; Tseng et al., 2013). 
Unlike pro-IL-1β, pro-IL-18 is constitutively expressed in many cell types and therefore does not 
require priming (Stutz et al., 2009). 
Interestingly, most resting cells also require priming signals to induce transcription of the 
scaffold proteins NLRP3 and AIM2 (Bauernfeind et al., 2009; von Moltke et al., 2013). Thus, in 
these cells, the presence of an NLRP3 or AIM2 agonist without priming is not sufficient to 
induce their respective inflammasomes, whereas for the NLRP1 and NLRC4 inflammasomes, 
inflammasome activation is independent of priming. Like pro-IL-1β, NLRP3 priming is mediated 
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via NF-κB (Bauernfeind et al., 2009); however, AIM2 expression is induced by type I interferon 
signaling rather than NF-κB (Rathinam et al., 2010). The PAMPs and DAMPs that stimulate 
inflammasome assembly are typically different from those that prime cells; it is rare for one 
signal to serve both functions. It is hypothesized that this two-signal control mechanism helps to 
limit inadvertent secretion of IL-1β, which is a highly potent pyrogen, and restricts its release to 
actual instances of infection or injury (Hornung and Latz, 2010). 
The mechanisms through which inflammasome scaffolds are activated by their 
respective signals are still under investigation. Studies in which the NLRP1 inflammasome was 
biochemically reconstituted have revealed that its minimal components are NLRP1, a 
ribonucleoside triphosphate, and caspase-1, and that this reconstituted NLRP1 inflammasome 
can be activated by MDP (Faustin et al., 2007). Though there is currently no direct evidence of 
MDP-NLRP1 binding, it has been proposed that NLRP1 binds MDP directly and that this 
interaction triggers NLRP1 oligomerization and caspase-1 activation (Franchi et al., 2012). 
Additionally, NLRP1 has been shown to undergo autoproteolytic cleavage (D'Osualdo et al., 
2011). Studies also indicate that the intracellular PRR protein NOD2 forms a complex with 
NLRP1 in response to MDP (Hsu et al., 2008); however, it is not known whether these events 
play a role in NLRP1 induction. Similar to the mechanism proposed for NLRP1 activation, the 
inflammasome scaffold AIM2 directly binds its ligand, dsDNA (Hornung et al., 2009). AIM2 is a 
member of the PYHIN family, rather than the NLR family, and therefore contains a pyrin domain 
and a HIN200 DNA-binding domain (Fernandes-Alnemri et al., 2009). AIM2 is located in the 
cytosol, where it detects dsDNA from viruses or intracellular bacteria, and where its exposure to 
self-DNA is restricted under normal conditions (Rathinam et al., 2012a). When the HIN200 
domain engages dsDNA, AIM2 activates inflammasome assembly via its pyrin domain 
(Rathinam et al., 2010). 
 Whereas AIM2, and possibly NLRP1, are activated by directly binding their ligands, the 
NLRC4 scaffold interacts with cofactor proteins that serve as the direct receptors (Kofoed and 
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Vance, 2011; Zhao et al., 2011). In mouse macrophages, flagellin induces NLRC4, and this is 
mediated by bacterial type III secretion systems (T3SS) and type IV secretion systems (T4SS) 
that facilitate entry of flagellin into the cytosol where it can interact with NLRC4 cofactor proteins 
(Miao et al., 2006; Miao and Warren, 2010). T3SS inner rod proteins also trigger murine NLRC4 
independently of flagellin (Miao et al., 2010b). The receptors that bind these ligands belong to 
the NLR family, apoptosis inhibitory protein (NAIP) group of proteins. Binding of flagellin by 
NAIP5 or NAIP6 enables the NAIP to complex with NLRC4, inducing inflammasome assembly. 
Similarly, T3SS inner rod proteins are physically recognized by NAIP2, which activates NLRC4 
(Kofoed and Vance, 2011; Zhao et al., 2011). Humans have only one NAIP homologue, which 
binds T3SS needle proteins, such as CprI of Chromobacterium violaceum, and induces NLRC4 
(Zhao et al., 2011). 
As mentioned above, the NLRP3 inflammasome is induced by physically and chemically 
diverse entities. Bacteria such as Listeria monocytogenes and Stapholococcus aureus, viruses 
including influenza A, and fungi such as Candida albicans have been demonstrated to activate 
NLRP3 (Allen et al., 2009; Craven et al., 2009; Hise et al., 2009; Kim et al., 2010). NLRP3 also 
responds to microbial products including bacterial pore-forming toxins and the potassium 
ionophore nigericin (Franchi et al., 2012; Mariathasan et al., 2006). Additionally, NLRP3 detects 
many types of DAMPs, such as extracellular ATP, hyaluronan, and an assortment of insoluble 
substances and particulates, including asbestos fibers, silica crystals, MSU crystals, cholesterol 
crystals, and amyloid-β (Aβ) (Duewell et al., 2010; Halle et al., 2008; Hornung et al., 2008; 
Mariathasan et al., 2006; Yamasaki et al., 2009). The diversity of these activators suggests that 
they activate a common downstream pathway or set of pathways that lead to NLRP3 induction, 
rather than binding NLRP3 directly. 
Several models for NLRP3 activation have been proposed. A number of NLRP3 agonists 
trigger potassium efflux, leading to low intracellular potassium levels, which is proposed to 
activate NLRP3. For example, NLRP3 induction by extracellular ATP is mediated by potassium 
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efflux resulting from activation of the P2X7 receptor, an ATP-gated cation channel (Mariathasan 
et al., 2006). Microbial pore-forming toxins and nigericin also cause intracellular potassium 
depletion, and blocking potassium efflux with high extracellular potassium inhibits NLRP3 
inflammasome activity (Jin and Flavell, 2010). 
Another model hypothesizes that NLRP3 agonists induce the generation of reactive 
oxygen species (ROS), leading to NLRP3 activation. In accordance with this hypothesis, ROS 
scavengers inhibit NLRP3 inflammasome induction by asbestos fibers, MSU crystals, and ATP 
(Dostert et al., 2008). It has also been found that ROS generated by damaged mitochondria 
activate NLRP3. Consequently, blocking the autophagic degradation of mitochondria causes 
ROS-producing mitochondria to accumulate, triggering NLRP3 (Zhou et al., 2011). Thioredoxin-
interacting protein (TXNIP), which binds the oxidoreductase thioredoxin under basal conditions, 
has been proposed to dissociate from thioredoxin in response to elevated ROS and 
subsequently interact with and activate NLRP3 (Zhou et al., 2010). However, it has also been 
reported that ROS inhibitors do not block NLRP3 induction, but rather prevent its expression 
(Bauernfeind et al., 2011b). 
A third model proposes a mechanism for NLRP3 activation by crystalline or particulate 
matter (Figure 2) (Hornung et al., 2008). In this model, these substances must be phagocytosed 
in order to activate NLRP3, as compounds that interfere with phagocytosis by disrupting 
cytoskeletal dynamics, such as cytochalasin D, block NLRP3 induction. Following phagocytosis, 
particulate materials destabilize phagolysosomes, and it is proposed that the leakage of certain 
lysosomal enzymes into the cytosol induces NLRP3. Disruption of lysosomes without particulate 
matter via osmotic shock or the lysosomotropic agent L-leucyl-L-leucine methyl ester (Leu-Leu-
OMe) also triggers NLRP3. The lysosomal enzymes implicated in NLRP3 induction include the 
cysteine proteases cathepsin B and cathepsin L (Duewell et al., 2010; Halle et al., 2008; 
Hornung et al., 2008). Inhibition or deletion of either enzyme partially but significantly 
suppresses NLRP3 inflammasome activation by lysosomal destabilization. These findings  
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Figure 2. Schematic diagram representing model of NLRP3 inflammasome activation by 
lysosomal destabilization. (A) Domain architecture of the components of the NLRP3 
inflammasome. Inflammasome assembly is mediated by homotypic interactions between pyrin 
domains on NLRP3 and ASC, and between caspase recruitment domains (CARDs) on ASC and 
caspase-1. (B) Two-signal model in which priming signals (signal 1) induce expression of 
NLRP3 and pro-IL-1β via NF-κB. Lysosomal destabilization (signal 2) causes leakage of 
lysosomal enzymes into the cytosol. These enzymes, such as cathepsins B and L, mediate 
NLRP3 inflammasome assembly, resulting in caspase-1 activation. Caspase-1 processes pro-
IL-1β into mature IL-1β, which is then secreted, and also drives pyroptosis. LRR, leucine-rich 
repeat; NBD, nucleotide-binding domain. 
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suggest that cathepsins B and L are redundant with respect to NLRP3 activation, and it is 
possible that other lysosomal enzymes also perform this function. The mechanism by which 
lysosomal enzymes activate NLRP3 remains unclear, but a recent study has reported that 
cathepsins B and L mediate NLRP3 inflammasome assembly by degrading NLRP10, a NLR 
with inhibitory effects on the NLRP3 inflammasome (Murphy et al., 2013). When lysosomes are 
intact, NLRP10 binds ASC, preventing it from associating with NLRP3. Following lysosomal 
damage, cathepsins B and L are released into the cytosol and degrade NLRP10, allowing 
NLRP3 to interact with ASC and thus inducing inflammasome formation. 
It is unclear which model of NLRP3 induction is most accurate, and it is plausible that 
more than one pathway mediates NLRP3 activation. Furthermore, the processes in these 
models, potassium efflux, ROS generation, and lysosomal destabilization, are highly 
interrelated. For example, both lysosomal destabilization and agents that induce potassium 
efflux, such as extracellular ATP and nigericin, also trigger mobilization of calcium into the 
cytoplasm from the endoplasmic reticulum (Murakami et al., 2012). Calcium mobilization, in 
turn, can cause mitochondrial damage and ROS generation. Thus, the interplay among these 
pathways makes the dissection of their individual contributions challenging. 
In addition to the canonical NLRP3 inflammasome consisting of NLRP3, ASC, and 
caspase-1, evidence indicates that NLRP3 participates in a “non-canonical inflammasome” that 
is dependent on caspase-11 and is activated in response to “non-canonical” NLRP3 stimuli such 
as Gram-negative bacteria and cholera toxin B (Kayagaki et al., 2011; Rathinam et al., 2012b). 
Like the canonical NLRP3 inflammasome, the non-canonical inflammasome mediates IL-1β/IL-
18 processing and programmed cell death. The non-canonical inflammasome requires caspase-
1 for processing of IL-1β and IL-18, but caspase-1 activation is dependent on caspase-11, in 
addition to NLRP3 and ASC. Agents that induce the NLRP3 inflammasome independently of 
caspase-11 are considered canonical and include extracellular ATP, crystalline or particulate 
matter, pore-forming toxins, and nigericin. Interestingly, NLRP3, ASC, and caspase-1 are 
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dispensable for the induction of cell death (Kayagaki et al., 2011). Further research is required 
to obtain a more complete understanding of the mechanisms of non-canonical inflammasome 
regulation, activation, and function. 
 
The NLRP3 inflammasome in disease 
 
Among the inflammasomes, the NLRP3 inflammasome has the most well characterized 
role in pathology. Autosomal dominant gain-of-function mutations in the NLRP3 gene are 
responsible for a family of autoinflammatory disorders known as cryopyrin-associated periodic 
syndromes (CAPS), or cryopyrinopathies, referring to NLRP3 by its former name, cryopyrin 
(Kubota and Koike, 2010; Shinkai et al., 2008). CAPS consist of a spectrum of three disorders 
of differing severity. The most mild of these is familial cold autoinflammatory syndrome (FCAS), 
formerly known as familial cold-induced urticaria. Muckle-Wells syndrome (MWS) is of 
intermediate severity, whereas neonatal-onset multisystem inflammatory disease (NOMID), also 
known as chronic infantile neurologic cutaneous and articular syndrome, is the most serious. 
Characteristic symptoms of FCAS include flares of rash, fever, and joint pain induced by 
exposure to cold. In MWS, these symptoms are more chronic and can occur spontaneously in 
addition to being provoked by cold or stress. Additionally, up to 60% of MWS patients develop 
sensorineural hearing loss, and systemic amyloid A amyloidosis occurs in roughly 25% of MWS 
patients, progressively leading to renal dysfunction (Church et al., 2008; Posch et al., 2012). 
NOMID, the most severe of the trio, not only causes fever, rash, and joint pain, but also involves 
inflammation of the central nervous system that, if left untreated, can result in substantial 
physical disabilities, mental impairment, and neurological issues such as chronic meningitis 
(Goldbach-Mansky, 2011). 
NLRP3 mutations associated with CAPS result in an overactive NLRP3 inflammasome 
(Shinkai et al., 2008). Consistent with this fact, the symptoms of CAPS are mediated by the IL-1 
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pathway, and targeted inhibition of IL-1β or the IL-1 receptor (IL-1R) using agents such as the 
IL-1R antagonist anakinra, the monoclonal anti-IL-1β antibody canakinumab, or the IL-1 “trap” 
fusion protein rilonacept have shown substantial success in treating CAPS (Kubota and Koike, 
2010). Notably, some CAPS patients do not have mutations in Nlrp3; approximately 50% of 
NOMID patients do not exhibit Nlrp3 mutations (Aksentijevich et al., 2002). It is unclear whether 
mutations in other inflammasome-related genes are involved in these cases, or if mutations in a 
separate pathway can also produce CAPS symptoms. 
While mutations in NLRP3 can cause illness, wild-type NLRP3 also mediates a number 
of diseases, many of which involve inflammatory responses to crystalline or particulate matter. 
For example, gout results from high serum levels of uric acid, leading to the deposition of MSU 
crystals in joints and surrounding tissues (Martinon et al., 2006). These MSU crystals are 
internalized by myeloid cells and activate the NLRP3 inflammasome via lysosomal 
destabilization, resulting in the IL-1β secretion that mediates gout symptoms (Hornung et al., 
2008). The related condition pseudogout arises from the deposition of calcium pyrophosphate 
dihydrate crystals in joints, where they also induce NLRP3-mediated inflammation (Martinon et 
al., 2006). Similarly, NLRP3 activation by articular hydroxyapatite crystals contributes to the 
pathogenesis of osteoarthritis (Jin et al., 2011). The lung pathologies silicosis and asbestosis 
result from the inhalation of crystalline silica dust and asbestos fibers, respectively (Cassel et 
al., 2008). Lung alveolar macrophages phagocytose these insoluble substances, activating 
NLRP3. The resulting inflammation induces pulmonary fibrosis, impairing lung function. It is 
notable that alum crystals, which constitute the most widely used adjuvant in human vaccines, 
derive their adjuvant properties from their ability to induce the NLRP3 inflammasome 
(Eisenbarth et al., 2008; Li et al., 2007).  
NLRP3 also appears to be involved in age-related diseases associated with chronic 
inflammation such as Alzheimer’s disease. In vitro, NLRP3 is activated in microglia, the myeloid-
derived resident immune cells of neural tissues, by phagocytosis of Aβ, a major component of 
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amyloid plaques associated with Alzheimer’s disease (Halle et al., 2008). In vivo, levels of active 
caspase-1 are significantly higher in brains from Alzheimer’s disease patients than those of age-
matched control individuals without neurological disease (Heneka et al., 2013). Furthermore, 
using the APP/PS1 mouse model of Alzheimer’s-like pathology, deletion of either Nlrp3 or 
Casp1 protected mice from cognitive impairment and reduced the accumulation of Aβ deposits 
in mouse brains (Heneka et al., 2013). 
Evidence also implicates the NLRP3 inflammasome in the pathogenesis of 
atherosclerosis (Duewell et al., 2010). In the early lesions of atherosclerosis, cholesterol crystals 
have been found colocalized with macrophages. Ingestion of cholesterol crystals by 
macrophages in vitro induces the NLRP3 inflammasome via phagolysosomal destabilization 
and the activity of cathepsins B and L. Furthermore, the LDLR-deficient mouse model of 
hypercholesterolemia has been utilized to evaluate the contribution of the NLRP3 
inflammasome to atherosclerosis. LDLR-deficient mice were reconstituted with bone marrow 
from NLRP3-deficient, ASC-deficient, or wild-type mice and fed a high cholesterol diet. Despite 
similarly high plasma cholesterol levels, mice reconstituted with NLRP3- or ASC-deficient bone 
marrow are significantly protected from the development of atherosclerotic lesions compared to 
mice reconstituted with wild-type bone marrow. Contrary to this study, a report utilizing the 
ApoE-deficient mouse model of hypercholesterolemia found that double deletion of ApoE and 
Nlrp3, Asc, or Casp1 does not protect mice from atherogenesis (Menu et al., 2011). However, 
two other papers have reported that ApoE-/-Casp1-/- double knockout mice have reduced areas 
of atherosclerotic lesions compared to ApoE single knockouts (Gage et al., 2012; Usui et al., 
2012). Additional research is warranted to clarify the nature of the discrepancies and to resolve 
the role of NLRP3 in atherosclerosis. 
Growing evidence points to a role for NLRP3 in the pathogenesis of type 2 diabetes 
mellitus (T2DM). T2DM results from insulin resistance coupled with substantial loss of 
pancreatic islet β-cell function and mass (Ahren, 2005; Prentki and Nolan, 2006). Several 
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studies have demonstrated an improvement in glucose tolerance and insulin sensitivity in mice 
lacking NLRP3 or ASC (Stienstra et al., 2011; Vandanmagsar et al., 2011; Wen et al., 2011; 
Youm et al., 2011). Evidence suggests that the NLRP3 inflammasome contributes to obesity-
induced insulin resistance by mediating IL-1β secretion from adipose tissue macrophages in 
response to the saturated fatty acid palmitate and/or the fatty acid derivatives known as 
ceramides (Vandanmagsar et al., 2011; Wen et al., 2011). Furthermore, IL-1β released by 
pancreatic macrophages or islet cells, which have also been found to express NLRP3 
inflammasome components, contributes to β-cell death (Masters et al., 2010; Zhou et al., 2010). 
High glucose concentrations trigger islet cells to secrete modest levels of IL-1β in an NLRP3-
dependent manner (Zhou et al., 2010). This glucose-induced IL-1β production was ROS-
mediated, and in accordance with the proposed TXNIP-mediated mechanism of NLRP3 
induction by ROS, islet cells from TXNIP-deficient mice secrete substantially less IL-1β than 
wild-type cells in response to high glucose. Furthermore, T2DM is highly associated with the 
accumulation of amyloid deposits in pancreatic islets, which contributes to the loss of β-cells. 
The main constituent of these deposits is islet amyloid polypeptide, which activates the NLRP3 
inflammasome in macrophages and dendritic cells, resulting in IL-1β release (Masters et al., 
2010). A recent study has also found that omega-3 fatty acids block the induction of the NLRP3 
inflammasome in macrophages by a variety of agonists, and that feeding mice the omega-3 
fatty acid docosahexaenoic acid inhibits the development of high-fat diet-induced insulin 
resistance in a NLRP3-dependent manner (Yan et al., 2013). 
While the role of the inflammasomes has been most extensively studied in myeloid-
derived hematopoietic cells, NLRP3 inflammasome activity in non-myeloid cells has been also 
been demonstrated. The best-documented role of NLRP3 in non-myeloid cells thus far is in 
intestinal homeostasis. Inflammatory bowel diseases, including Crohn’s disease and ulcerative 
colitis, are characterized by chronic inflammation within the gastrointestinal tract (Zaki et al., 
2011). In studies using the dextran sodium sulfate (DSS) mouse model of colitis, drinking water 
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is supplemented with DSS, which is toxic to the colonic epithelium (Dupaul-Chicoine et al., 
2010). Under normal conditions, the colonic epithelium maintains a barrier that restricts gut 
microflora to the intestinal lumen. Following exposure to DSS, this protective epithelial barrier is 
disrupted, enabling intestinal microbes and luminal antigens to enter subepithelial tissues and 
trigger inflammation (Zaki et al., 2010). Interestingly, deletion of Nlrp3, Asc, or Casp1 results in 
increased susceptibility of mice to DSS-induced colitis, suggesting that the NLRP3 
inflammasome plays a protective role (Allen et al., 2010; Dupaul-Chicoine et al., 2010; Hirota et 
al., 2011; Zaki et al., 2010). Bone marrow transplantation experiments indicate that this effect is 
due to NLRP3 inflammasome activity in a non-myeloid tissue (Dupaul-Chicoine et al., 2010; 
Zaki et al., 2010). Levels of IL-18, but not IL-1β, significantly increase following DSS exposure in 
wild-type, but not Casp1-/- mice, and injection of Casp1-/- mice with recombinant IL-18 rescues 
them from DSS-induced colitis, demonstrating that IL-18 is responsible for mediating the 
protection conferred by the NLRP3 inflammasome. Furthermore, isolated colonic epithelial cells 
were shown to produce IL-18 via the inflammasome (Zaki et al., 2010). The NLRP3 
inflammasome and IL-18 were found to mediate their protective effects by inducing tissue repair 
via epithelial cell proliferation (Dupaul-Chicoine et al., 2010; Zaki et al., 2010). In addition, 
NLRP3 inflammasome activity in hematopoietic cells was found to play a protective role against 
colitis-associated tumorigenesis (Allen et al., 2010). However, other studies have reported that 
the NLRP3 inflammasome and IL-18 contribute to DSS-induced colitis (Bauer et al., 2010; 
Siegmund et al., 2001; Sivakumar et al., 2002). These contrasting results are likely due to 
differences in the genetic backgrounds of the mice used, their intestinal microflora, and the 
pleiotropic effects of IL-18 (Bauer et al., 2012; Dupaul-Chicoine et al., 2010). Nevertheless, the 
findings from studies of colitis demonstrate that activation of the NLRP3 inflammasome in non-
myeloid cells can contribute significantly to physiological and pathological processes. 
Several generalizations can be made regarding the pathologies that involve the NLRP3 
inflammasome. First, NLRP3 frequently mediates chronic inflammatory responses to insoluble 
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deposits. Several of these, such as Alzheimer’s disease, atherosclerosis, and T2DM, are age-
associated diseases in which insoluble material accumulates over time. Second, although 
inflammasome activity has primarily been observed in hematopoietic cells of the myeloid 
lineage, some pathological conditions involve NLRP3 activity in local non-myeloid cells, such as 
pancreatic islet cells in T2DM and intestinal epithelial cells in colitis; the range of cells capable 
of NLRP3 inflammasome activity has yet to be elucidated. Finally, although NLRP3 
inflammasome activity frequently contributes to pathology, in some instances it does play a 
protective role. 
 
Features of AMD pathology 
 
The insoluble deposits known as drusen are the hallmarks of AMD, and early AMD is 
clinically diagnosed based on the detection of drusen and/or pigmentation alterations in the 
macula by ophthalmoscopy (Seddon et al., 2006). Drusen deposition is localized to the basal 
side of the RPE, in the vicinity of BrM (Figure 1). BrM, located between the RPE and CC, is an 
elastic lamina consisting of five layers. In order of their location from the RPE to the CC, these 
layers are: the RPE basal lamina, the inner collagenous layer, the elastic layer, the outer 
collagenous layer, and the CC basal lamina. Drusen accumulate between the RPE basal lamina 
and the inner collagenous layer (Mullins et al., 2000). Drusen can also be classified as “hard” or 
“soft” based on their appearance. Hard drusen are small with sharp, well-defined edges, 
whereas soft drusen are larger and have indistinct borders. The number, size, and confluence of 
drusen are risk factors for AMD progression (Klein et al., 2007). Whereas the presence of one 
or two small hard drusen in the macula is common in older individuals and confers only minimal 
likelihood of progression to late AMD, approximately eight or more small hard drusen 
significantly increase the incidence of soft drusen. In turn, the number and area of soft drusen 
are associated with a higher risk of developing advanced AMD. 
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Drusen are heterogeneous in composition, but their most abundant components are 
lipids. Unesterified and esterified cholesterol, phosphatidylcholine, sphingomyelin, and fatty 
acids are common constituents of drusen, with esterified cholesterol and phosphatidylcholine 
comprising at least 40% of drusen volume (Wang et al., 2010). In addition to lipids, drusen 
include apolipoproteins, advanced glycation end-products (AGEs), complement components 
and factors, vitronectin, immunoglobulins, acute-phase reactants, prothrombin, crystallins and 
amyloid proteins such as Aβ (Buschini et al., 2011; Crabb et al., 2002; Hageman et al., 2001; 
Hageman et al., 1999; Rudolf et al., 2008). Notably, many of these molecules have known roles 
in immune processes and inflammation. The origin of drusen is unresolved, with plasma and the 
RPE proposed as the most likely sources (Hageman et al., 2001; Wang et al., 2009). Similarly 
unclear is the relationship between drusen and AMD and whether it is cause or effect. Thus, the 
role of drusen in the pathogenesis of AMD remains a matter of debate. However, the fact that 
drusen are insoluble deposits, similar to those found in atherosclerotic plaques or Alzheimer’s 
disease, led to the hypothesis that their internalization could activate the NLRP3 inflammasome 
via the lysosomal pathway. 
Besides drusen, the outer retina of the aging eye also accumulates other deposits, 
including basal laminar deposits (BLamD), basal linear deposits (BLinD), and reticular 
pseudodrusen. BLamD are found between the RPE plasma membrane and its basal lamina, 
and are comprised of basal lamina proteins and long-spacing collagen (Sarks et al., 2007). 
BLinD, on the other hand, are lipid-rich deposits of membranous material. Similar to drusen, 
BLinD are located between the RPE basal lamina and the inner collagenous layer of BrM and 
are associated specifically with AMD (Bhutto and Lutty, 2012; Curcio and Millican, 1999). While 
drusen, BLinD, and BLamD are located basal to the RPE, reticular pseudodrusen are situated in 
the subretinal space, between the retina and the apical surface of the RPE (Querques et al., 
2013). Also known as subretinal drusenoid deposits, reticular pseudodrusen are associated with 
late AMD, but not as strongly as soft drusen (Zweifel et al., 2010). As hypothesized for drusen, 
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the material present in BLamD, BLinD, and reticular pseudodrusen could potentially activate the 
inflammasome if phagocytosed. 
In addition to extracellular deposits, AMD is also associated with the accumulation of 
lipofuscin in RPE lysosomes. Lipofuscin consists of pigmented granular substances that are not 
degradable by lysosomal digestion (Terman and Brunk, 2004). Accordingly, lipofuscin is found 
in the lysosomes of many long-lived, postmitotic cell types including neurons and cardiac 
myocytes. During their lifetime, RPE cells continuously phagocytose outer segment discs that 
are shed by photoreceptors as part of the visual cycle (Holz et al., 1999; Sparrow et al., 2010). 
As such, lipofuscin components, including a variety of bisretinoid compounds, are derived from 
the outer segment discs. The bisretinoid fluorophore N-retinylidene-N-retinylethanolamine 
(A2E), which has historically been considered a major constituent of RPE lipofuscin (Sparrow et 
al., 1999; Wielgus and Roberts, 2012), although this has recently been challenged (Ablonczy et 
al., 2013), possesses detergent-like properties and has been reported to destabilize lysosomal 
membranes (Schutt et al., 2002; Sparrow et al., 2006).  
Therefore, the development of AMD is associated with exposure of RPE cells to 
extracellular deposits and intralysosomal lipofuscin, both of which have the potential to cause 
lysosomal disruption. Moreover, A2E can alkalinize RPE lysosomes, whose acidic pH enables 
optimal activity of lysosomal degradative enzymes (Bergmann et al., 2004; Holz et al., 1999). 
The increased pH leads to reduced function of lysosomal enzymes, causing the accumulation of 
undegraded material. Thus, A2E present in RPE lipofuscin may induce pH-mediated lysosomal 
dysfunction with subsequent lysosomal membrane destabilization. 
 
Inflammation and AMD 
 
Several lines of evidence suggest a role for inflammation in the pathogenesis of AMD. 
Although features such as the blood-ocular barrier and immunosuppression by molecules such 
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as transforming growth factor-β maintain a level of immune privilege in the eye, cells of the 
innate immune system are nonetheless present in the retina and able to mediate inflammation 
(Stein-Streilein, 2013). Microglia are the primary resident immune cell of the retina (Lee et al., 
2008), and macrophages and dendritic cells can infiltrate the retina from the choroid in 
situations where the blood-RPE barrier is disrupted (Eter et al., 2008). 
Arguably the most compelling evidence for the contribution of inflammation to AMD 
comes from studies that have strongly implicated the complement system. A major component 
of the innate immune system, the complement system combats microbial infection by several 
effector mechanisms including the induction of inflammatory responses. Complement consists 
of a number of proteins circulating in the blood or bound to cell membranes. Activation of 
complement occurs via proteolytic cascades and can be initiated via any of three pathways: the 
classical pathway, the alternative pathway, and the lectin pathway. A number of genetic studies 
have determined that a SNP in complement factor H (CFH) that changes amino acid residue 
402 from a tyrosine to a histidine (Y402H) is associated with a significantly increased risk for 
developing AMD. Possession of at least one such allele increases the risk for AMD by 2.7-fold 
and accounts for 40-50% of the population attributable risk for AMD (Edwards et al., 2005; 
Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005). CFH, a key regulator of 
complement activity, inhibits the proteolytic induction of the alternative pathway in order to 
protect host cells from complement effector functions such as inflammation. The Y402H variant 
of CFH binds several of its ligands with reduced affinity, impairing its recruitment and 
decreasing its effectiveness at restricting complement activation. CFH is known to bind C-
reactive protein, which is found in drusen and is elevated in the BrM and CC of AMD patients 
compared to similarly aged control individuals, and this interaction is weakened by the Y402H 
polymorphism (Laine et al., 2007; Ormsby et al., 2008; Yu et al., 2007). The Y402H variant also 
has reduced affinity for glycosaminoglycans, CFH ligands present in BrM and on the RPE 
surface (Clark et al., 2010). Furthermore, levels of CFH are decreased in the BrM and CC of 
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AMD patients compared to aged control donors (Bhutto et al., 2011). These findings have led to 
the hypothesis that autoinflammation mediated by complement dysregulation may promote 
AMD (Anderson et al., 2010). 
In addition, a SNP encoding a phenylalanine (F) at amino acid 412 instead of leucine (L) 
in TLR3, a PRR involved in innate immune detection of double-stranded RNA (dsRNA), is 
significantly associated with protection from GA (Yang et al., 2008). Primary cultured RPE cells 
heterozygous for the TLR3 L and F variants exhibit a 50% reduction in TLR3-mediated 
cytotoxicity in response to the dsRNA analog polyinosinic:polycytidiylic acid, compared to cells 
homozygous for the L variant, supporting the concept that the protection from GA conferred by 
the TLR3 F variant is due to a reduction in TLR3 function. Interestingly, TLR3 induction by 
dsRNA molecules of at least 21 nucleotides in length protects mice from laser injury-induced 
CNV (Kleinman et al., 2008). This observation suggests that inflammation may play 
independent roles in the pathogenesis of GA and neovascular AMD. However, analyses of 
subfoveal neovascular membranes from patients with wet AMD have detected an abundance of 
inflammatory cells such as macrophages (Oh et al., 1999). It has been postulated that 
inflammatory cytokines secreted by macrophages, including IL-1β, may stimulate RPE cells to 
produce VEGF, thereby promoting CNV. Accordingly, depletion of macrophages using 
liposomal clodronate reduces the extent of laser-induced CNV in mice (Espinosa-Heidmann et 
al., 2003; Sakurai et al., 2003). 
The seemingly contradictory roles of inflammation in CNV have been proposed to be 
due to the differential contributions of classically activated and alternatively activated 
macrophages (Ambati et al., 2013). Stimulation of macrophages with molecules such as LPS or 
the Th1-type cytokine interferon-γ results in classical activation, also known as M1 activation 
(Classen et al., 2009). Conversely, the alternatively activated, or M2, macrophage phenotype is 
induced by the Th2-type cytokines IL-4 and IL-13 (Lawrence and Natoli, 2011; Tugal et al., 
2013). M1 macrophages are pro-inflammatory, whereas M2 macrophages are anti-
 27 
inflammatory, promote angiogenesis, and facilitate wound healing and tissue repair (Cao et al., 
2011; Lawrence and Natoli, 2011). Therefore, contrasting effects of innate immune processes in 
CNV may be due to the highly divergent roles of M1 and M2 macrophages. 
Many constituents of drusen have documented roles in immune-related or inflammatory 
processes, and drusen deposits and atherosclerotic plaques share many constituents, indicating 
that AMD may be mediated by inflammatory processes similar to those at play in 
atherosclerosis (Mullins et al., 2000). For instance, the NLRP3 agonist Aβ is detected both in 
drusen and in Alzheimer’s disease plaques (Halle et al., 2008; Johnson et al., 2002; Liu et al., 
2013). AGEs, a category of chemically modified proteins and lipids also present in drusen, as 
well as in aged RPE and BrM, accumulate with age and promote inflammation (Glenn et al., 
2009; Xu et al., 2009; Yamada et al., 2006). AGEs are associated with a number of other age-
related diseases including T2DM, atherosclerosis, osteoarthritis, and Alzheimer’s disease, 
further supporting the involvement of inflammation in these pathologies (Reddy and Beyaz, 
2006). 
Despite the immune privileged nature of the retina, sera from AMD patients contain 
significantly higher titers of autoantibodies against retinal antigens than that of age-matched 
controls, leading some to postulate an autoimmune component in AMD (Buschini et al., 2011; 
Gurne et al., 1991; Mullins et al., 2000; Patel et al., 2005; Penfold et al., 1990). Notably, eyes 
from AMD patients have been found to contain significantly more proteins adducted to the 
oxidative stress product carboxyethylpyrrole (CEP) than eyes from age-matched control 
individuals, and autoantibodies against CEP are substantially elevated in the plasma of AMD 
patients compared to age-matched individuals without AMD (Crabb et al., 2002; Gu et al., 
2003). Immunization of mice with CEP adducted to mouse serum albumin (MSA) results in RPE 
degeneration reminiscent of GA that correlates with anti-CEP antibody titer (Hollyfield et al., 
2008). 
It is important to note that many age-associated pathologies of the developed world, 
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including atherosclerosis, T2DM, and neurodegenerative diseases, involve a low-grade 
inflammatory process that is intermediate between classic, frank inflammation and the basal 
state. This milder form of inflammation has been termed para-inflammation (Medzhitov, 2008). 
Whereas classic inflammation occurs in response to insults such as infection or tissue injury and 
is normally resolved, para-inflammation appears to be the body’s attempt to rectify more 
moderate perturbations from homeostasis such as tissue stress or malfunction. If dysfunctional 
conditions persist, para-inflammation is not resolved and becomes chronic and pathological. In 
the context of AMD, tissue stress and malfunction could be induced by oxidative stress, drusen 
deposition, AGE accumulation, and RPE lipofuscin buildup, as well as other insults. 
 
The NLRP3 inflammasome and AMD 
 
Myeloid-derived cells such as microglia and macrophages are potential mediators of 
NLRP3 inflammasome-induced inflammation in AMD. In addition, it has been found that certain 
non-immune cells that have barrier functions, such as keratinocytes, also express 
inflammasome components, enabling them to carry out some functions of myeloid cells 
(Dupaul-Chicoine et al., 2010; Feldmeyer et al., 2007; Watanabe et al., 2007; Yazdi et al., 2010; 
Yilmaz et al., 2010; Zaki et al., 2010). Similarly, we have shown that RPE cells, which represent 
the outer retinal barrier and contribute to retinal immune privilege, express the NLRP3 
inflammasome (Tseng et al., 2013). Recent reports have provided important information 
regarding the potential role of the NLRP3 inflammasome in AMD. One study found that drusen 
isolated from AMD eyes induces the NLRP3 inflammasome in macrophages and dendritic cells 
in vitro (Doyle et al., 2012). This study also demonstrates that the complement protein C1Q, a 
constituent of drusen, activates NLRP3 in myeloid-derived cells via phagolysosomal disruption. 
Two additional reports demonstrate that RPE cells do indeed exhibit NLRP3 inflammasome 
activity (Tarallo et al., 2012; Tseng et al., 2013). In one of these reports, the accumulation of 
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RNA transcripts expressed from the Alu retrotransposon in RPE cells was shown to trigger 
NLRP3 via mitochondrial ROS, leading to inflammasome-mediated IL-18 secretion (Tarallo et 
al., 2012). 
Interestingly, these studies have come to contrasting conclusions regarding the 
involvement of NLRP3 in AMD. In the CEP-MSA immunization mouse model of GA, NLRP3 and 
cleaved caspase-1 colocalize with the macrophage marker F4/80, implying that NLRP3 
inflammasome activity in GA occurs in macrophages (Doyle et al., 2012). In contrast, GA was 
hypothesized to be mediated by Alu-induced NLRP3 inflammasome activity in RPE cells without 
the requirement of immune cells (Tarallo et al., 2012). While one report implicates NLRP3 
inflammasome activity and IL-18 secretion as mediators of GA (Tarallo et al., 2012), the other 
suggests that NLRP3 and IL-18 protect against CNV induced by laser injury (Doyle et al., 2012). 
It is possible that NLRP3-mediated IL-18 plays differential roles in GA and neovascular AMD but 
clearly further investigation is necessary to elucidate this question. 
Whereas IL-18 has been implicated in the pathogenesis of AMD, a role for IL-1β in AMD 
has yet to be identified. Unlike IL-18, processing of IL-1β by the inflammasome requires a 
priming signal to induce expression of pro-IL-1β. As such, it is possible that the mouse models 
of AMD pathology used in the studies described above supplied signals that induced NLRP3 
inflammasome assembly, but not priming. Consistent with this hypothesis, Alu RNA transcript 
accumulation activates NLRP3 in RPE cells but does not upregulate pro-IL-1β (Tarallo et al., 
2012). Thus, I was interested to determine whether RPE cells could secrete IL-1β when 
appropriate priming signals are provided. The findings that drusen deposits activate NLRP3 in 
myeloid cells, that the drusen component C1Q induces NLRP3 via lysosomal destabilization, 
and that RPE cells express NLRP3 inflammasome components suggest that exposure of RPE 
cells to AMD-related substances such as drusen or lipofuscin may activate NLRP3. Therefore, 
the work in this thesis aimed to test the hypothesis that lysosomal destabilization activates the 
NLRP3 inflammasome in RPE cells, and that RPE cells secrete mature IL-1β if primed with an 
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NF-κB agonist to induce expression of pro-IL-1β prior to inflammasome activation. This was 
accomplished by: evaluating the expression of NLRP3 in the RPE in vitro and in vivo; 
determining if pro-IL-1β expression could be induced in RPE by priming; assessing the effect of 
priming on the levels of individual components of the NLRP3 inflammasome; evaluating the 
ability of lysosomal destabilization to activate the inflammasome in RPE cells; and 
characterizing the effects of inflammasome induction in RPE cells, with particular emphasis on 
IL-1β processing and the cell death mechanism pyroptosis. 
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CHAPTER 2 
 
 
 
EXPRESSION OF NLRP3 INFLAMMASOME COMPONENTS AND  
INFLAMMASOME PRIMING IN RPE CELLS 
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PREFACE 
 
The Results and Discussion sections of this chapter are adapted from portions of the article, 
“NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: 
implications for age-related macular degeneration,” by W.A. Tseng, T. Thein, K. Kinnunen, K. 
Lashkari, M.S. Gregory, P.A. D’Amore, and B.R. Ksander in Investigative Ophthalmology & 
Visual Science, January 2013, Vol. 54, No. 1, pages 110-120, the copyright of which is held by 
The Association for Research in Vision and Ophthalmology, Inc. Although the Results and 
Discussion of this chapter have been largely reproduced from parts of the original article, 
adaptations have been made to include data on hfRPE cells in Figures 5 and 6 and in the text of 
the Results section, to improve readability of the figures when displayed in the format of this 
dissertation, to maintain uniformity of abbreviations, and to better blend copied segments into 
the context of the chapter and the dissertation as a whole. 
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RATIONALE 
 
Whereas inflammasomes have been most heavily studied in hematopoietic cells of the 
myeloid lineage, such as monocytes and macrophages, non-myeloid cells such as keratinocytes 
and intestinal epithelial cells have been demonstrated to express components of the NLRP3 
inflammasome and to activate the NLRP3 inflammasome (Feldmeyer et al., 2007; Watanabe et 
al., 2007; Yilmaz et al., 2010; Zaki et al., 2010). Epithelial cells constitute the barriers that 
separate the body from the external environment or delimit a bodily compartment with restricted 
immune cell access. It has therefore been suggested that the inflammasome activity of these 
non-myeloid cells may complement the innate immune system by rapidly responding to 
pathogens or tissue damage (Yazdi et al., 2010). The RPE helps to maintain the blood-retinal 
barrier that contributes to retinal immune privilege, and thus it is reasonable that they express 
and can activate the NLRP3 inflammasome. 
Each of the components of the NLRP3 inflammasome, NLRP3, ASC, and procaspase-1, 
plays a critical role in the inflammasome (Latz et al., 2013). The scaffold protein NLRP3 detects 
PAMPs and DAMPs via mechanisms that remain unclear. When activated, NLRP3 binds the 
adaptor protein ASC via homotypic pyrin domain interactions. In turn, ASC recruits procaspase-
1 into the complex via their CARDs, leading to the autocatalytic activation of caspase-1, the 
primary effector enzyme of the inflammasome. Caspase-1 processes cytokine precursors into 
their mature forms through proteolytic cleavage. The IL-1β precursor, pro-IL-1β, is one of the 
best-characterized substrates of caspase-1. However, transcription of pro-IL-1β is not 
constitutive, but requires pro-inflammatory stimulation in a step known as “priming,” which is 
mediated by NF-κB. Additionally, in many cell types including human and mouse macrophages, 
NLRP3 is not expressed under basal conditions and also requires priming (Bauernfeind et al., 
2009). In the course of the pathogenesis of AMD, it is thought that numerous inflammation-
related molecules, including complement proteins and other molecules present in drusen, 
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accumulate in the vicinity of the RPE. I speculate that these AMD-associated molecules may 
prime the RPE, leading to the upregulation of pro-IL-1β and NLRP3. 
Thus, I propose that RPE cells express the components of the NLRP3 inflammasome, 
and that priming with NF-κB agonists will induce RPE cells to express pro-IL-1β. This chapter 
reports the evaluation of the expression of NLRP3 in human eyes, the expression of NLRP3 
inflammasome components in cultured RPE cells, and the ability of NF-κB-activating agents to 
prime RPE cells to express pro-IL-1β. As priming may be required for NLRP3 expression and 
could also affect ASC and procaspase-1, the effect of priming on the levels of NLRP3 
inflammasome components was also examined. 
 
RESULTS 
 
NLRP3 is localized to the RPE and drusen of the eyes of patients with AMD 
 
I first sought to determine whether NLRP3 is expressed by human RPE in vivo, and 
whether there are qualitative differences between its presence in patients with AMD, in the form 
of GA or neovascular AMD, and age-matched individuals without AMD. Outer retinal sections 
were collected from two donors with GA, two donors with neovascular AMD, and three age-
matched donors that were unaffected by AMD. The sections were stained with an antibody 
against NLRP3 or an isotype control (Figure 3). As a positive control of NLRP3 expression, 
human conjunctival tissue corresponding to each eye was also stained with the same 
antibodies. NLRP3 (red, arrowheads) was detected in the RPE of eyes affected by either GA or 
neovascular AMD; there was no staining in sections from the same donors with the control 
antibody. Several sections from GA-affected eyes contained drusen within the transitional zone, 
and there was substantial extracellular NLRP3 staining both in choroidal cells beneath BrM and 
on the basal side of RPE cells adjacent to areas of drusen (Figure 3, A and B). NLRP3 was also  
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Figure 3. Expression of NLRP3 in AMD-affected eyes. Retinas from donors with (A-C) GA, 
(D-F) neovascular AMD, or (G) unaffected eyes were stained for NLRP3. NLRP3 (red, 
arrowheads) was detected in the RPE of eyes affected with either form of AMD. (A, B) 
Representative sections of the transitional zone in eyes with GA shows areas of staining in the 
choroidal cells just beneath BrM (A, arrowheads) as well as in the basal side of the RPE 
adjacent to confluent drusen (B, arrowheads). Some drusen deposits in GA eyes also stained 
for NLRP3. (D, E) Representative sections just outside the area of choroidal neovascularization 
display staining in the vicinity of thickened BrM as well as in basal RPE (D, arrowheads). 
NLRP3 staining was also seen within the thickened BrM representing basal linear deposits (E, 
arrowheads). (C, F) There was no detectable signal in sections from the same donors stained 
with an isotype control. (G) A representative section from an age-matched donor unaffected by 
AMD did not exhibit any NLRP3 expression. 
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detected extracellularly in the vicinity of thickened BrM (Figure 3D) and associated with basal 
linear deposits (Figure 3E) in eyes with neovascular AMD outside the area of choroidal 
neovascularization as well as in basal RPE (Figure 3D). NLRP3 was only detected at sites of 
GA or neovascular lesions in AMD eyes and was not observed in the RPE of lesion-free areas 
of the retina. In contrast to AMD-affected eyes, there was not detectable NLRP3 staining in 
outer retinal sections from eyes of age-matched donors unaffected by AMD. 
 
NLRP3 is expressed in human RPE cells in vitro 
 
 Motivated by the observation of NLRP3 in RPE of AMD patients, I investigated the 
expression of NLRP3 by RPE cells in vitro using the human RPE cell line ARPE-19. ARPE-19 
cells were cultured on Transwell membranes for four weeks to allow them to polarize and form 
tight junctions, characteristics of differentiated RPE in vivo. Immunocytochemical localization 
revealed NLRP3 distributed in a punctate pattern throughout the cells (Figure 4A). Confocal 
microscopy indicated that NLRP3 was preferentially localized toward the basal aspect of the 
cells (Figure 4A). 
Next, I evaluated NLRP3 protein expression in ARPE-19 cells by immunoblotting (Figure 
4B). Two methods were used to definitively identify the NLRP3 band in western blotting: specific 
knockdown of NLRP3 with siRNA against NLRP3 and the inclusion of a positive control that 
consisted of cells that were transfected with NLRP3. ARPE-19 cells cultured in plastic wells 
were transfected with a pool of 4 siRNAs against NLRP3 (siNLRP3) or a non-targeting control 
siRNA pool. Table 1 lists the target sequences of the siRNAs in each pool. A band migrating 
slightly above 100 kDa, which is consistent with the predicted molecular weights of known 
NLRP3 isoforms, was detected in the control-transfected cells and was reduced by 77% using 
siNLRP3 (Figure 4B) (Kummer et al., 2007). The identity of this band as NLRP3 was further 
confirmed using a lysate of HEK293T cells overexpressing NLRP3 tagged with DDK (identical to  
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Figure 4. Expression of NLRP3 in human RPE cells in vitro. (A) ARPE-19 cells were 
cultured on Transwell membranes for four weeks to form a polarized monolayer. Monolayers 
were fixed, permeabilized, and stained for NLRP3 (red) and with DAPI to reveal nuclei (blue). Z-
stacks of polarized monolayers were generated using confocal microscopy. (B) ARPE-19 cells 
grown on plastic wells were transfected with an siRNA pool against human NLRP3 or a control 
siRNA pool. ARPE-19 lysates were subjected to immunoblotting for NLRP3, with α-tubulin as a 
loading control. Densitometry was performed using ImageJ (NIH). Tubulin-normalized NLRP3 
band densities are presented as their value relative to the control. (C) The lysates of ARPE-19 
cells were compared to those of HEK293T cells overexpressing DDK-tagged NLRP3 
(HEK293T-NLRP3) and a mock-transfected HEK293T lysate (HEK293T-Mock) to confirm the 
identify of the NLRP3 band. THP-1 cells served as a reference for NLRP3 levels in a cell type 
with known NLRP3 inflammasome activity. Lysates were immunoblotted for NLRP3, with α-
tubulin as a loading control, and reprobed for the DDK tag fused to the NLRP3 overexpressed in 
HEK293T cells. 
 38 
Table 1. Target sequences of siRNAs used in this study. Pooled siRNA against NLRP3 and 
a non-targeting control siRNA pool were obtained from Dharmacon. Each pool contains 4 
siRNAs, whose target sequences are presented above. 
 
siRNA Pool Target Sequences 
NLRP3 #1 – 5’-GCAAGACCAAGACGUGUGA-3’ 
#2 – 5’-GAAGUGGGGUUCAGAUAAU-3’ 
#3 – 5’-UGCAAGAUCUCUCAGCAAA-3’ 
#4 – 5’-GGAUCAAACUACUCUGUGA-3’ 
Control #1 – 5’-UGGUUUACAUGUCGACUAA-3’ 
#2 – 5’-UGGUUUACAUGUUGUGUGA-3’ 
#3 – 5’-UGGUUUACAUGUUUUCUGA-3’ 
#4 – 5’-UGGUUUACAUGUUUUCCUA-3’ 
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FLAG). The ~100 kDa band observed in lysates of ARPE-19 co-migrated with a protein that was 
heavily enriched in the NLRP3-overexpressing lysate compared to mock-transfected HEK293T 
lysate (Figure 4C). A band at this molecular weight is also present in the human monocytic 
leukemia cell line THP-1, which has been demonstrated to express NLRP3 and is known to 
have NLRP3 inflammasome activity (Kanneganti, 2010; Niemi et al., 2011; Rajamaki et al., 
2010). Reprobing the same blot with an anti-DDK tag antibody revealed that the enriched band 
in the NLRP3-overexpressing HEK293T lysate is indeed NLRP3. Taken together, these results 
conclusively demonstrate the expression of NLRP3 by ARPE-19 cells. 
 
Priming of RPE cells with NF-κB agonists induces pro-IL-1β expression 
 
I next sought to determine if ARPE-19 cells could be primed to express pro-IL-1β, a 
classical inflammasome substrate. In myeloid cells, pro-IL-1β expression is induced by priming 
with a NF-κB activating stimulus such as LPS (Hiscott et al., 1993; Schroder and Tschopp, 
2010). To determine if NF-κB agonists prime ARPE-19 cells, the cells were treated with LPS, IL-
1α, or TNFα at concentrations of 4 ng/ml and 50 ng/ml for 24 or 48 hours. Immunoblotting of 
ARPE-19 lysates revealed that while pro-IL-1β was barely detectable in the absence of NF-κB 
agonists, treatment with IL-1α or TNFα induced pro-IL-1β expression, with IL-1α inducing the 
highest levels (Figure 5A). In contrast, LPS did not upregulate pro-IL-1β under the conditions 
tested, an observation that is consistent with the fact that the levels of TLR4 are markedly 
reduced in ARPE-19 compared to primary RPE (Gnana-Prakasam et al., 2008).  
Due to the extent of its priming activity, IL-1α was selected for use in subsequent 
experiments. Thus, I further evaluated the dose- and time-dependency of the induction of pro-
IL-1β by IL-1α. Confluent ARPE-19 cells were treated with an IL-1α dose curve for 48 hours 
(Figure 5B) or with 4 ng/ml IL-1α for a range of times up to 48 hours (Figure 5C). Pro-IL-1β was 
induced by IL-1α in a dose-dependent manner. Detectable levels of pro-IL-1β were expressed in  
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Figure 5. Priming of RPE cells by inducers of NF-κB. (A) ARPE-19 cells grown to confluence 
on plastic wells were treated with the NF-κB activating agents LPS, IL-1α, or TNFα at a 
concentration of 4 ng/ml or 50 ng/ml for 24 hr or 48 hr, or were left untreated as a negative 
control (Ctrl). (B and C) Confluent ARPE-19 cells were treated with increasing concentrations of 
IL-1α for 48 hr (B) or 4 ng/ml IL-1α for increasing lengths of time (C). (D) hfRPE cells were 
treated in duplicate with a range of concentrations of IL-1α, or 100 ng/ml LPS, for 24 hr. Cell 
lysates were immunoblotted for pro-IL-1β, after which blots were stripped and reprobed for 
GAPDH as a loading control. Densitometry was performed using ImageJ (NIH), and GAPDH-
normalized band intensities are displayed for each condition. 
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response to the lowest dose of IL-1α evaluated, approximately 1.5 ng/ml. Doubling the IL-1α 
dose to roughly 3.1 ng/ml resulted in a nearly threefold increase in pro-IL-1β levels. Each 
additional twofold increase in IL-1α dose, up to 25 ng/ml, the maximum dose tested, induced a 
1.3- to 1.5-fold upregulation in pro-IL-1β. Treatment of ARPE-19 cells with 4 ng/ml IL-1α 
upregulated pro-IL-1β expression in a time-dependent fashion. At three hours, pro-IL-1β was 
barely detectable, and this level roughly doubled by six hours. Between six and twelve hours, 
pro-IL-1β levels increased by approximately 4.5-fold. From twelve to 24 hours, pro-IL-1β was 
further upregulated by 1.8-fold, at which point levels of pro-IL-1β reached a maximum, changing 
minimally between 24 and 48 hours.  
After observing that molecules such as IL-1α can prime ARPE-19 cells to express pro-IL-
1β, the effect of IL-1α on primary human fetal RPE (hfRPE) cells was evaluated. hfRPE cells 
were treated with a dose curve of IL-1α up to 100 ng/ml (Figure 5D); other hfRPE cells were 
treated with 100 ng/ml LPS as a comparison. As expected, pro-IL-1β was not expressed by 
unprimed hfRPE cells but, similar to ARPE-19 cells, the addition of IL-1α led to a dose-
dependent increase in the expression of pro-IL-1β. LPS did not induce pro-IL-1β in hfRPE cells. 
 
Expression of NLRP3 inflammasome components in human RPE cells 
 
ARPE-19 cells were next evaluated for the expression of the critical NLRP3 
inflammasome components ASC and procaspase-1. In addition, I examined the effect of priming 
on the expression of NLRP3, ASC, and procaspase-1. In addition to inducing the expression of 
pro-IL-1β, priming has also been reported to increase the expression of other inflammasome 
components, including NLRP3, in some cell types such as mouse macrophages (Bauernfeind et 
al., 2009). ARPE-19 cells were treated with a dose-curve of IL-1α up to 25 ng/ml, and lysates 
were immunoblotted for NLRP3, ASC and caspase-1. 
NLRP3 was expressed by ARPE-19 cells in the absence of priming, and its expression  
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Figure 6. Effect of priming on expression of NLRP3 inflammasome components in human 
RPE cells. ARPE-19 cells were treated with (A, B, and C) increasing concentrations of IL-1α for 
48 hours or (D) with 4 ng/ml IL-1α for a time course up to 48 hours. Lysates were 
immunoblotted for (A) NLRP3, (B) ASC, or (C and D) procaspase-1. (E) hfRPE cells were 
treated in duplicate with a range of concentrations of IL-1α for 24 hours, and lysates were 
immunoblotted for NLRP3. All blots were stripped and reprobed for GAPDH or α-tubulin as a 
loading control. Densitometry was performed using ImageJ, and band intensities were 
normalized to GAPDH or α-tubulin. Densitometry results are expressed as a fold-change 
compared to unprimed cells. 
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was largely unresponsive to IL-1α (Figure 6A). Maximal NLRP3 induction of 1.6-fold was 
achieved at 25 ng/ml IL-1α, the highest IL-1α dose tested (Figure 6A). Similarly, ASC was 
expressed under basal conditions and was not increased by treatment with IL-1α (Figure 6B). 
On the other hand, procaspase-1 was expressed under unprimed conditions but its levels were 
further increased by IL-1α in a dose-dependent manner, reaching a maximal induction of five- to 
six-fold when stimulated by 12.5 ng/ml IL-1α or higher (Figure 6C). The time-dependency of 
procaspase-1 upregulation was evaluated by treating ARPE-19 cells with 4 ng/ml IL-1α for a 
range of times up to 48 hours. Procaspase-1 levels increased throughout the time course, 
reaching a five-fold induction at 48 hours (Figure 6D). The effect of priming on NLRP3 
expression was also assessed in primary hfRPE cells (Figure 6E). Like ARPE-19 cells, hfRPE 
cells expressed NLRP3 under basal conditions, and the levels of NLRP3 were not further 
increased by treatment with IL-1α. 
 
DISCUSSION 
 
These data establish an association between characteristics of human AMD and NLRP3 
expression by RPE. I detected NLRP3 protein in the RPE of donor human eyes affected by 
AMD, but not in eyes of age-matched controls. NLRP3 expression in vivo was associated with 
both GA and neovascular AMD, and was detected both intracellularly in the RPE as well as 
extracellularly in drusen and in the vicinity of BrM, likely released from dying RPE cells. These 
results also demonstrate the expression of NLRP3 inflammasome components by RPE cells in 
vitro and the induction of the IL-1β precursor, pro-IL-1β, by RPE cells. Studies in myeloid cells 
have shown that NF-κB-mediated priming signals induce the expression of both NLRP3 and 
pro-IL-1β (Bauernfeind et al., 2009), and we speculate that molecular changes in the outer 
retina that occur during the pathogenesis of AMD, such as the accumulation of proinflammatory 
molecules in drusen deposits (Ambati et al., 2013), may induce these changes in RPE. 
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It is unclear whether the association of NLRP3 expression with GA and neovascular 
AMD reflects shared events in their pathogeneses or are a common result of distinct processes, 
as their etiologies are currently unsolved. Dry AMD can lead to neovascular AMD (Imrie and 
Bailey, 2007), suggesting common events in their development. However, some cases of 
neovascular AMD occur in the absence of dry AMD, and it is hypothesized that neovascular 
AMD and GA have differing etiologies, with CC degeneration and drusen-mediated RPE atrophy 
proposed as their initial insults, respectively (Bhutto and Lutty, 2012). However, CC loss may 
occur secondary to RPE deterioration, and vice versa, so neovascular AMD and GA may share 
common pathological features, but dissimilar initial insults. It is likely that NLRP3 upregulation is 
induced by one or more of these shared characteristics. 
Unlike the pigment epithelium in vivo, RPE cells in vitro expressed NLRP3 without 
proinflammatory stimulation. This is likely due to culture conditions where cells are released 
from contact inhibition in the process of isolation and subsequent trypsinization and are 
continuously exposed to elevated levels of stimulators present in the serum. The unstimulated 
ARPE-19 and hfRPE cells, however, did not express pro-IL-1β, indicating that culture conditions 
do not entirely mimic conditions of priming. Priming ARPE-19 or hfRPE cells with IL-1α induced 
pro-IL-1β expression. The finding that LPS did not induce pro-IL-1β expression in ARPE-19 
cells is consistent with previous reports that whereas primary RPE cells express the LPS 
receptor TLR4, it is downregulated in ARPE-19 cells (Gnana-Prakasam et al., 2008; Kindzelskii 
et al., 2004; Kumar et al., 2004). However, the inability of LPS to prime sixth- to eighth-passage 
hfRPE cells suggests that expression of TLR4 or a downstream signaling molecule may decline 
with passage in culture. 
The identity of the molecule(s) that might prime the RPE in the context of AMD is not 
known. As the expression of pro-IL-1β is downstream of NF-κB, any molecule that activates NF-
κB is a potential priming agent (Hiscott et al., 1993; Schroder and Tschopp, 2010). Although IL-
1α was the most potent priming agent evaluated in this study, I also found that TNFα induced 
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RPE cells to express pro-IL-1β. TNFα, which has been localized in choroidal neovascular 
membranes obtained from AMD-affected eyes (Oh et al., 1999; Wang et al., 1999), regulates 
several activities in RPE cells, such as attachment, spreading, and migration (Jin et al., 2000; 
Yang et al., 2005), and has been implicated in the development of laser-induced CNV (Jasielska 
et al., 2010; Lichtlen et al., 2010). Additionally, higher levels of proteins adducted to CEP have 
been detected in eyes from donors with AMD than in age-matched controls (Hollyfield et al., 
2008). CEP-adducted human serum albumin (HSA) has been shown to prime murine and 
human macrophages and mononuclear cells (Doyle et al., 2012), so it is plausible that CEP 
adducts act similarly on RPE cells. Thus, although the specific stimuli that prime RPE cells in 
AMD remain uncertain, it is clear that NLRP3 is upregulated in the RPE of eyes afflicted with 
AMD. Thus, one or more of the molecular changes in the outer retina that are associated with 
AMD prime the NLRP3 inflammasome in human RPE cells. 
 
CAVEATS, LIMITATIONS, AND POTENTIAL RESOLUTIONS 
 
It is important to note a caveat associated with the immunohistochemistry of human 
ocular sections described in this chapter, which detected NLRP3 in the RPE of eyes affected by 
advanced AMD (Figure 3). The antibody used for NLRP3 immunohistochemistry is the same 
antibody that was used for NLRP3 immunoblotting (Figure 4), where it can be seen that it 
yielded a number of prominent non-specific bands. It is the case that the same antisera did not 
yield any labeling in the sections of retinas from donor eyes without AMD. However, to be 
entirely confident in the staining, it would be important to verify the specificity of the 
immunohistochemistry. An appropriate control to assess antibody specificity would be to stain 
with antisera that had been immunoabsorbed with the antibody’s immunizing peptide. Use of 
immunoabsorbed antisera would eliminate specific staining and any labeling observed would be 
deemed non-specific.
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CHAPTER 3 
 
 
 
ACTIVATION OF THE NLRP3 INFLAMMASOME IN RPE CELLS  
VIA LYSOSOMAL DESTABILIZATION 
 47 
PREFACE 
 
The Results and Discussion sections of this chapter are adapted from portions of the article, 
“NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: 
implications for age-related macular degeneration,” by W.A. Tseng, T. Thein, K. Kinnunen, K. 
Lashkari, M.S. Gregory, P.A. D’Amore, and B.R. Ksander in Investigative Ophthalmology & 
Visual Science, January 2013, Vol. 54, No. 1, pages 110-120, the copyright of which is held by 
The Association for Research in Vision and Ophthalmology, Inc. Figures 8 and 10 have been 
added to include data on hfRPE cells and the text of the Results and Discussion sections have 
been adapted to reflect this new data. 
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RATIONALE 
 
NLRP3 inflammasome activity is regulated at two levels by signals associated with 
cellular danger, such as pathogen infection or tissue damage (Rathinam et al., 2012a). Certain 
signals induce the activation of the NLRP3 scaffold protein, resulting in inflammasome assembly 
and activation of caspase-1, whereas other signals are responsible for the transcriptional 
induction of pro-IL-1β, in a process known as priming. In many cell types, priming signals are 
also necessary for the expression of NLRP3 (Bauernfeind et al., 2009). I have demonstrated 
that RPE cells express all of the components of the inflammasome: NLRP3, ASC, and 
procaspase-1. I have also shown that priming RPE cells with NF-κB agonists such as IL-1α 
induces expression of pro-IL-1β. However, it remains to be seen whether the NLRP3 
inflammasome can be activated in RPE cells. The danger signals that activate the NLRP3 
inflammasome are numerous and chemically diverse, and include extracellular ATP, microbial 
pore-forming toxins, and a wide variety of crystals and insoluble particles or aggregates (Franchi 
et al., 2012). The crystals and insoluble substances that have been demonstrated to induce the 
NLRP3 inflammasome include Aβ, asbestos fibers, and crystals of MSU, calcium 
pyrophosphate dihydrate, silica, cholesterol, or alum. 
Crystalline or insoluble matter has been reported to induce the NLRP3 inflammasome 
via a mechanism involving lysosomal destabilization (Duewell et al., 2010; Halle et al., 2008; 
Hornung et al., 2008). Evidence suggests a model in which crystals and particles are 
internalized into endosomes or phagosomes, which fuse with lysosomes. Crystals and 
particulate matter damage the endolysosomal or phagolysosomal membrane, leading to the 
leakage of lysosomal enzymes such as cathepsins into the cytosol where they mediate 
signaling that activates NLRP3. The mechanism through which NLRP3 is activated remains 
unclear, but may involve degradation of an inhibitory NLR, NLRP10 (Murphy et al., 2013). In 
support of this model of mechanical destabilization of the lysosomes, blockade of phagocytosis 
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by disrupting cytoskeletal dynamics abrogates crystal-induced inflammasome activation 
(Duewell et al., 2010; Halle et al., 2008; Hornung et al., 2008). Similarly, preventing the activity 
of pH-sensitive lysosomal enzymes by inhibiting lysosomal acidification suppresses crystal-
mediated NLRP3 inflammasome induction. In addition, activation of the NLRP3 inflammasome 
by crystals is partially but significantly inhibited by genetic deletion or pharmacological blockade 
of cathepsin B or cathepsin L. Furthermore, phagocytosis-independent disruption of lysosomes 
using the lysosomotropic compound Leu-Leu-OMe also induces the NLRP3 inflammasome via 
lysosomal enzymes including cathepsin B. 
During AMD pathogenesis, RPE cells are exposed to insoluble material in the form of 
drusen deposits that accumulate between the basement membrane of the RPE and the inner 
collagenous layer of BrM. Drusen have a heterogeneous composition and are comprised of 
lipids such as cholesterol and proteins such as vitronectin, complement proteins, and amyloid 
proteins (Hageman et al., 1999; Isas et al., 2010; Wang et al., 2010). Phagocytosis of the 
drusen components Aβ and complement protein C1Q by myeloid-derived cells induces the 
NLRP3 inflammasome via lysosomal destabilization (Doyle et al., 2012; Halle et al., 2008). 
Furthermore, incubation of myeloid cells with drusen isolated from AMD-affected eyes activates 
the NLRP3 inflammasome (Doyle et al., 2012). In addition to drusen deposition, AMD 
pathogenesis also involves the accumulation of a pigmented, granular substance called 
lipofuscin in RPE lysosomes. RPE lipofuscin is believed to be the product of incomplete 
degradation of phagocytosed material. A2E, a constituent of RPE lipofuscin, has detergent-like 
properties and has been demonstrated to disrupt lysosomal membranes (Schutt et al., 2002; 
Sparrow et al., 2006). 
In light of the involvement of lysosomal disruption in NLRP3 inflammasome activation in 
myeloid-derived cells, the accumulation of potential sources of RPE lysosomal damage during 
AMD progression, and the presence of NLRP3 inflammasome components in RPE cells, I 
hypothesize that lysosomal destabilization induces the NLRP3 inflammasome in RPE cells. This 
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chapter presents evidence demonstrating that chemical disruption of RPE lysosomes triggers 
inflammasome activation, as evidenced by the activation of caspase-1 and the induction of 
inflammasome effector functions such as IL-1β processing and caspase-1-dependent 
programmed cell death, known as pyroptosis. 
 
RESULTS 
 
Lysosomal destabilization in RPE cells activates caspase-1 
 
Having found that ARPE-19 cells expressed the components of the NLRP3 
inflammasome (Chapter 2), I assessed whether the destabilization of their lysosomes would 
lead to inflammasome activation as measured by the activation of caspase-1, and I evaluated 
the involvement of lysosomal enzymes in this process. The lysosomotropic agent Leu-Leu-OMe, 
which is converted within the lysosome to membranolytic derivatives by dipeptidyl peptidase I 
(DPP-I), was used to disrupt lysosomes (Thiele and Lipsky, 1990). Staining with acridine 
orange, which fluorescently labels DNA and RNA as green and lysosomes as red, was used to 
assess the effects of Leu-Leu-OMe on lysosomal integrity (Figure 7A). Whereas control ARPE-
19 cells contained red punctate structures characteristic of intact lysosomes, treatment with 1 
mM Leu-Leu-OMe triggered a loss of lysosomal staining indicative of lysosomal destabilization. 
Caspase-1 activation was evaluated using the fluorescent labeled inhibitor of caspases 
(FLICA) probe FAM-YVAD-FMK that specifically labels active caspase-1. While activated 
caspase-1 was undetectable in untreated ARPE-19 cells, treatment with 1 mM Leu-Leu-OMe for 
2 hours induced significant caspase-1 activation (Figure 7, B and C). To control for the 
possibility that effects of Leu-Leu-OMe unrelated to lysosomal destabilization were responsible 
for inflammasome activation, a DPP-I inhibitor (Gly-Phe-CHN2) was used to block the disruption 
of lysosomes by Leu-Leu-OMe. Addition of Gly-Phe-CHN2 30 minutes prior to Leu-Leu-OMe  
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Figure 7. Lysosomal destabilization activates caspase-1 in ARPE-19 cells. (A) ARPE-19 
cells were stained with 5 µM acridine orange for 30 minutes and treated for 30-45 minutes with 
1 mM Leu-Leu-OMe or control buffer. Fluorescence microscopy was used to detect acridine 
orange sequestered in lysosomes (red) or bound to DNA or RNA (green). Scale bars, 50 µm. 
(B) ARPE-19 cells were primed with 4 ng/ml IL-1α for 48 hours. Cells were treated with 1 mM 
Leu-Leu-OMe for 2 hours to disrupt lysosomes, or left untreated (Control). Lysosomal 
destabilization induced by Leu-Leu-OMe was blocked by inhibiting DPP-I via addition of 10 µM 
Gly-Phe-CHN2 to cells 30 minutes before addition of Leu-Leu-OMe. The lysosomal proteases 
cathepsins B and L were inhibited using 50 µM Z-FF-FMK. Active caspase-1 was detected by 
the FLICA probe FAM-YVAD-FMK (green). Nuclei were labeled by staining with Hoechst 33342 
(blue). Scale bars, 100 µm. (C) Green active caspase-1 signal was quantified and normalized to 
number of nuclei. Numerical data are represented as mean ± standard error of the mean (SEM); 
n = 3. * indicates P<0.01 vs. Control; § indicates P<0.01 vs. Leu-Leu-OMe with no inhibitor. 
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abrogated its ability to activate the inflammasome (Figure 7, B and C), supporting the 
conclusion that lysosomal destabilization triggers the NLRP3 inflammasome in ARPE-19 cells. 
Previous reports demonstrate that lysosomal enzymes, particularly cathepsins B and L, 
released from destabilized lysosomes play a critical role in the induction of the NLRP3 
inflammasome in myeloid cells (Duewell et al., 2010; Hornung et al., 2008; Rajamaki et al., 
2010). Therefore, the cathepsin B and L inhibitor Z-FF-FMK was used to assess the 
involvement of these lysosomal enzymes in NLRP3 activation in ARPE-19 cells (Iwata et al., 
2003; Ravanko et al., 2004). Pre-treatment with Z-FF-FMK significantly inhibited activation of 
caspase-1 by Leu-Leu-OMe (Figure 7, B and C), indicating a role for cathepsins B and/or L in 
NLRP3 inflammasome induction in RPE cells. 
After the demonstration that lysosomal disruption activated caspase-1 in ARPE-19 cells 
via a cathepsin-mediated mechanism, I evaluated inflammasome activity in primary hfRPE cells 
using the caspase-1 FLICA probe (Figure 8). The effects of priming and lysosomal 
destabilization on caspase-1 activation were assessed in hfRPE cells cultured on plastic (Figure 
8A) or maintained on Transwell membranes to induce polarization and maturation (Figure 8B). 
In the absence of lysosomal damage, no active caspase-1 was detected. However, disruption of 
lysosomal integrity with Leu-Leu-OMe triggered caspase-1 activation. Without priming, only 
minimal levels of active caspase-1 were observed, but substantially higher levels were 
generated in cells that were primed for 24 hours with IL-1α prior to Leu-Leu-OMe treatment. 
These results were similar whether hfRPE cells were maintained on Transwell membranes or 
grown on plastic. Furthermore, inhibition of DPP-I in order to prevent Leu-Leu-OMe-mediated 
lysosomal membrane disruption abrogated caspase-1 activation (Figure 8C). Inhibition of 
cathepsins B and L or cathepsin B alone also blocked caspase-1 activation in hfRPE cells by 
lysosomal destabilization (Figure 8C). 
 
Lysosomal destabilization in RPE cells induces IL-1β release and cytotoxicity 
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Figure 8. Lysosomal disruption activates caspase-1 in primary RPE cells. (A) hfRPE cells 
were grown to confluence on plastic wells or (B) maintained on Transwell membranes and were 
primed with 10 ng/ml IL-1α or treated with control buffer for 24 hours. Cells were then treated 
with 1 mM Leu-Leu-OMe or control buffer for 2 hours. Active caspase-1 (green) was detected 
with the FLICA probe FAM-YVAD-FMK, and Hoechst 33342 was used to stain nuclei (blue). (C) 
hfRPE cells maintained on Transwell membranes were primed with 10 ng/ml IL-1α for 24 hours. 
Appropriate wells were then treated with the DPP-I inhibitor Gly-Phe-CHN2 (10 µM), the 
cathepsin B and L inhibitor Z-FF-FMK (50 µM) and the selective cathepsin B inhibitor CA-074-
Me (50 µM). After 30 minutes, lysosomal disruption was induced by treatment with 1 mM Leu-
Leu-OMe for 2 hours. Active caspase-1 (green) was detected with FAM-YVAD-FMK, and phase 
contrast microscopy was used to image cell morphology. Scale bars: (A) 100 µm, (B) 50 µm, (C) 
100 µm. 
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I next investigated whether lysosomal disruption can induce release of mature IL-1β from 
primed cells. Although IL-1β ELISAs are much less sensitive for pro-IL-1β than the mature form 
(Herzyk et al., 1992), pro-IL-1β released from dying cells may be misinterpreted as low levels of 
cleaved IL-1β. Immunoblotting demonstrated that Leu-Leu-OMe triggered the release of mature 
IL-1β from IL-1α-primed ARPE-19 cells that co-migrated with recombinant human mature IL-1β 
(Figure 9A). Thus, specific detection of the mature form of IL-1β can only be achieved by 
immunoblotting of conditioned media, as it clearly distinguishes between mature IL-1β (17 kDa) 
and its precursor (31-35 kDa) by virtue of their molecular weights.  
After demonstrating that mature IL-1β is secreted by ARPE-19 cells treated with Leu-
Leu-OMe, I used ELISA to quantify the amount of IL-1β secreted and to investigate the 
mechanisms involved. Leu-Leu-OMe induced the release of approximately 40 pg/ml IL-1β after 
3 hours and this release was completely blocked by DPP-I inhibition, indicating that Leu-Leu-
OMe acted through lysosomal destabilization (Figure 9B). The selective caspase-1 inhibitor Z-
YVAD-FMK also significantly reduced IL-1β secretion, indicating that the lysosomal damage-
induced IL-1β release from ARPE-19 cells is mediated by caspase-1 and the inflammasome. 
Additionally, inhibition of cathepsins B and L using Z-FF-FMK blocked IL-1β secretion, 
supporting a role for these lysosomal enzymes in inflammasome activation in ARPE-19 cells. 
Treatment with Leu-Leu-OMe also caused substantial cytotoxicity, as assessed by 
lactate dehydrogenase (LDH) release. ARPE-19 cells treated with Leu-Leu-OMe for 3 hours 
exhibited 40-50% cell death (Figure 9B). As with IL-1β secretion, cytotoxicity induced by Leu-
Leu-OMe was completely blocked by inhibition of DPP-I or cathepsins B and L. Furthermore, 
the cell death caused by lysosomal disruption was completely suppressed by the caspase-1 
inhibitor, indicating an inflammasome-mediated death mechanism. 
Inflammasome-mediated IL-1β release (Figure 10A) and cell death (Figure 10B) were 
also evaluated in primary hfRPE cells. IL-1α-primed hfRPE cells treated with Leu-Leu-OMe 
released more than 60 pg/ml of IL-1β, as measured by ELISA. Consistent with the lack of pro-
 55 
 
Figure 9. ARPE-19 cells secrete IL-1β  and undergo pyroptotic cell death in response to 
lysosomal destabilization. (A) ARPE-19 cells primed with 15 ng/ml IL-1α for 48 hr were 
treated with 1 mM Leu-Leu-OMe (Leu) to disrupt lysosomes or received control buffer (Ctrl). 
After 3 hours, conditioned media (CM) were concentrated and immunoblotted to detect mature 
IL-1β (17 kDa) and distinguish it from its precursor (31-35 kDa). A serial dilution of 0-200 pg 
recombinant human IL-1β was used as reference. (B) IL-1β ELISA was performed on CM from 
ARPE-19 cells treated with 1 mM Leu-Leu-OMe. LDH release was quantified to evaluate 
cytotoxicity. The selective inhibitors Gly-Phe-CHN2 (5 µM), Z-YVAD-FMK (10 µM), and Z-FF-
FMK (50 µM) were used to block the activity of DPP-I, caspase-1, and cathepsins B and L, 
respectively. Data represent mean ± SEM of three experiments. * indicates P<0.01 vs. Control, 
§ indicates P<0.01 vs. Leu-Leu-OMe with no inhibitor. 
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Figure 10. Lysosomal destabilization induces IL-1β release and pyroptosis in human 
primary RPE cells. hfRPE cells were primed with 10 ng/ml IL-1α or treated with control buffer 
for 24 hours. The DPP-I inhibitor Gly-Phe-CHN2 (10 µM), the caspase-1 inhibitor Z-YVAD-FMK 
(10 µM), the cathepsin B and L inhibitor Z-FF-FMK (50 µM), and the selective cathepsin B 
inhibitor CA-074-Me (50 µM) were added to appropriate wells. After 30 minutes, 1 mM Leu-Leu-
OMe was added to destabilize lysosomes. Following a 3-hour incubation, conditioned media 
were collected. (A) ELISA was performed to quantify levels of IL-1β released into hfRPE 
conditioned media. (B) LDH levels in hfRPE conditioned media were quantified to evaluate 
cytotoxicity. Experiment was performed in triplicate, and data are represented as the mean ± 
standard deviation. 
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IL-1β expression in RPE cells under basal conditions, unprimed hfRPE cells did not release IL-
1β even when treated with Leu-Leu-OMe. Primed cells treated with Leu-Leu-OMe also exhibited 
30-40% cytotoxicity, as detected by LDH release. Cell death was significantly lower in unprimed 
hfRPE cells compared to primed cells. Lysosomal destabilization was required for both IL-1β 
release and cell death, as they were abrogated by inhibition of DPP-I. Blockade of cathepsins B 
and L significantly reduced IL-1β release and cytotoxicity, and inhibition of cathepsin B alone 
lowered IL-1β release and cell death to a similar degree, suggesting that cathepsin B is the 
predominant lysosomal enzyme involved in inflammasome activation in primary RPE cells. 
 
DISCUSSION 
 
Chemical disruption of lysosomes using Leu-Leu-OMe triggered inflammasome 
activation in RPE cells, as evidenced by the detection of active caspase-1, which mediated IL-
1β release and RPE cell death. Pre-treatment with Gly-Phe-CHN2 inhibited the intralysosomal 
conversion of Leu-Leu-OMe to membranolytic metabolites by DPP-I, preventing Leu-Leu-OMe-
mediated lysosomal destabilization and inflammasome activation. Blocking lysosomal 
destabilization abolished caspase-1 activation, IL-1β release, and RPE cytotoxicity. These 
results demonstrate that inflammasome activation and its downstream effects were induced by 
lysosomal destabilization, rather than unrelated effects of Leu-Leu-OMe. Additionally, the fact 
that inhibition of the lysosomal enzymes cathepsins B and L blocked lysosomal damage-
induced inflammasome activation, IL-1β release, and pyroptosis is consistent with previous 
reports implicating these enzymes as mediators of NLRP3 inflammasome assembly in myeloid-
derived cells (Duewell et al., 2010; Hornung et al., 2008). Whereas cathepsins B and L each 
played only a partial role in NLRP3 activation in myeloid cells, cathepsin B was responsible for a 
majority of the caspase-1 activation, IL-1β, and cell death induced by lysosomal destabilization 
in primary RPE cells, suggesting that cathepsin B is the predominant lysosomal enzyme 
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responsible for NLRP3 induction in the RPE. 
These results support a model in which RPE lysosomal damage results in the leakage of 
cathepsin B into the cytosol, where it activates NLRP3 through either direct interaction or an 
intermediary signaling pathway. A recent study reported a mechanism for the induction of 
NLRP3 inflammasome formation by phagolysosomal destabilization in glial cells, in which 
cathepsins B and L degrade NLRP10, a NLR that inhibits NLRP3 inflammasome assembly by 
binding ASC and preventing it from interacting with NLRP3 (Murphy et al., 2013). Therefore, 
release of cathepsins B and L from lysosomes into the cytosol facilitates NLRP10 degradation 
and mediates NLRP3 inflammasome activation. It is likely that this mechanism mediates NLRP3 
inflammasome formation in RPE cells as well. As expression of NLRP10 has not yet been 
reported in RPE cells, the possibility exists that another protein performs its function in the RPE. 
Intracellular pro-IL-1β has been reported to be produced by RPE cells (Planck et al., 
1993), but my finding is the first to demonstrate inflammasome-mediated processing of mature 
IL-1β from RPE cells. As expected, levels of IL-1β released from RPE cells are significantly 
lower than those released from myeloid cells in response to lysosomal disruption, which are on 
the order of 1 ng/ml (Hornung et al., 2008). The term “para-inflammation” has been coined to 
describe a response to tissue stress that is intermediate between inflammation and the basal 
state (Medzhitov, 2008). Such low-level inflammation is hypothesized to play a role in age-
related and inflammatory disorders such as AMD and atherosclerosis (Buschini et al., 2011; Xu 
et al., 2009). I speculate that the IL-1β released by RPE cells in response to lysosomal damage 
mediates para-inflammation, thus contributing to AMD. A number of AMD-associated insults 
could be responsible for RPE lysosomal destabilization and inflammasome activation during the 
pathogenesis of AMD. Isolated drusen deposits as well as the drusen components Aβ and 
complement factor C1Q have been shown to activate the NLRP3 inflammasome in myeloid cells 
(Doyle et al., 2012; Halle et al., 2008; Isas et al., 2010). Additionally, the formation of drusen is 
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hypothesized to occur due to exocytosis of undegraded waste material resulting from impaired 
lysosomal digestive capability (Ambati et al., 2013). Therefore, drusen deposition may be 
secondary to the accumulation of insoluble substances in lysosomes that could disrupt the 
lysosomal membrane. Furthermore, the lipofuscin component A2E, which accumulates in RPE 
lysosomes, has an amphiphilic molecular structure that grants it detergent-like chemical 
properties that disrupt lysosomal membranes (Schutt et al., 2002; Sparrow et al., 1999). 
I demonstrated that RPE cytotoxicity resulting from lysosomal destabilization is caspase-
1-dependent. This is characteristic of ‘pyroptosis,’ a mode of programmed cell death mediated 
by the inflammasome and caspase-1, rather than apoptotic caspases such as caspase-3 (Miao 
et al., 2010a). Although apoptosis and pyroptosis are both processes of regulated cell death, 
pyroptosis is a proinflammatory mode of cell death, whereas apoptosis is non-inflammatory. 
While the plasma membrane is speculated to remain intact during apoptosis, pyroptosis 
involves plasma membrane rupture and release of intracellular contents, allowing for its 
quantification by measurement of LDH release (Bergsbaken et al., 2009; Fernandes-Alnemri et 
al., 2009; Suzuki et al., 2007). Hence, I speculate that the inflammasome may contribute to 
AMD via both cytokine release and pyroptotic RPE death. 
The data reported here support a two-signal model of NLRP3 inflammasome induction 
by disruption of RPE lysosomes. Priming signals such as IL-1α, TNFα, or CEP adducts induce 
expression of pro-IL-1β and NLRP3. Disruption of RPE lysosomes, which may be caused by 
lipofuscin, drusen components, or other insoluble lysosomal contents, triggers NLRP3 
inflammasome assembly via lysosomal enzymes such as cathepsin B. The assembled 
inflammasome activates caspase-1, which cleaves pro-IL-1β to form mature IL-1β and also 
mediates pyroptotic RPE cell death. My results have shown that both priming and lysosomal 
damage must occur for RPE cells to release IL-1β. Furthermore, priming substantially elevates 
the levels of active caspase-1 generated following lysosomal destabilization, and priming also 
significantly increases pyroptosis. Although these processes are independent of pro-IL-1β 
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expression, they are likely enhanced by the upregulation of procaspase-1 induced by priming 
with IL-1α. 
Two recent studies present different hypotheses regarding the function of the NLRP3 
inflammasome pathway in AMD. One study using a mouse model of laser-induced CNV 
suggests that NLRP3 has a protective role in neovascular AMD by inducing IL-18 release from 
infiltrating macrophages, which in turn reduces VEGF secretion by RPE cells (Doyle et al., 
2012), whereas a second study using a mouse model of Alu RNA-induced GA suggests that 
NLRP3 plays a destructive role in dry AMD by inducing IL-18 secretion from RPE cells (Tarallo 
et al., 2012). Although it is plausible that IL-18 may protect against CNV via inhibition of VEGF 
production by RPE cells, the laser injury model of CNV is an acute wound-healing model that 
bears little mechanistic resemblance to neovascular AMD (Marneros, 2013). As previous 
studies suggest the NLRP3 inflammasome promotes epithelial tissue repair via IL-18 (Dupaul-
Chicoine et al., 2010; Zaki et al., 2010), it is likely that the protective effects of IL-18 in the laser-
induced CNV model are a reflection of its role in wound healing, rather than AMD. Nevertheless, 
it is possible that the NLRP3 inflammasome may have distinct roles in wet and dry advanced 
AMD, or even influence the development of one form over the other. 
The data presented in this chapter demonstrate that lysosomal destabilization can 
activate the NLRP3 inflammasome in RPE cells, inducing the secretion of the potent 
proinflammatory cytokine IL-1β from primed cells and pyroptosis. These processes may 
constitute novel mechanisms for AMD pathogenesis. The activators and effectors of the NLRP3 
inflammasome are consistent with the phenotype of AMD. Taken together with convincing 
genetic data that implicate a role for inflammation (Donoso et al., 2006; Gold et al., 2006; 
Hageman et al., 2005; Nozaki et al., 2006), our findings suggest a mechanism by which insults 
such as drusen deposition and lipofuscin accumulation can contribute to AMD pathology. 
 
CAVEATS, LIMITATIONS, AND POTENTIAL RESOLUTIONS 
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The experiments reported in this chapter to examine the biochemical mechanism of 
inflammasome activation in RPE cells have are limited by the fact that they rely on small 
molecule or peptide-based inhibitors of enzymes. Such inhibitors may have off-target activities 
that can confound the analyses of their effects. For example, peptide fluoromethyl ketones, such 
as the compounds Z-YVAD-FMK and Z-FF-FMK used in this study to inhibit caspase-1 and 
cathepsins B and L, respectively, can exhibit off-target inhibition via non-specific reaction of the 
fluoromethyl ketone moiety with active site cysteines of other enzymes. To account for this 
issue, experiments involving peptide fluoromethyl ketone inhibitors should include a negative 
control inhibitor. Z-FA-FMK is often used as a specificity control for experiments involving 
peptide fluoromethyl ketone inhibitors of caspases, as Z-FA-FMK does not specifically target 
caspases. However, Z-FA-FMK does target cathepsins B and L, which are believed to mediate 
NLRP3 inflammasome activation. Therefore, Z-FA-FMK is not a suitable control for this system. 
Instead, one could use an inhibitor of an apoptotic caspase, such as caspase-8, the initiator 
caspase of the extrinsic apoptotic pathway. Z-IETD-FMK is a peptide fluoromethyl ketone that 
targets caspase-8, and is not specific for caspase-1 or cathepsins. If off-target activity is 
responsible for the effects of Z-YVAD-FMK or Z-FF-FMK, then Z-IETD-FMK should produce 
similar results. 
An alternative approach to addressing the issue of inhibitor specificity is to deplete the 
protein levels of the enzymes of interest via RNA interference. The enzymes caspase-1, 
cathepsin B, and cathepsin L could be silenced via siRNA or shRNA in order to validate the 
results generated by the small molecule inhibitors. Furthermore, to ensure that the effects on 
inflammasome function are due to knockdown of the target gene, RPE cells can be transfected 
with an RNAi-resistant mutant version of the gene or its ortholog from a different species. 
Suppression of inflammasome activation or effector functions such as IL-1β processing or 
pyroptosis induction by the silencing of the enzyme, followed by rescue of inflammasome 
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activity by the RNAi-resistant mutant, would confirm the role of the enzyme suggested by the 
inhibitor studies. 
 
 63 
 
 
 
CHAPTER 4 
 
 
 
GENERAL DISCUSSION 
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The NLRP3 inflammasome plays a key role in the innate immune system. In response to 
a variety of signals indicative of microbial infection or tissue damage, the NLRP3 inflammasome 
mediates the processing and release of inflammatory cytokines such as IL-1β and IL-18. It also 
promotes a form of pro-inflammatory programmed cell death known as pyroptosis. However, the 
dysregulation of NLRP3 inflammasome activity can have highly detrimental effects. Pathological 
NLRP3 activity can occur as a result of gain-of-function mutations, as in the case of the CAPS 
spectrum of disorders, or due to the accumulation of NLRP3 agonists including insoluble 
particles, crystals, or aggregates that activate NLRP3 via lysosomal destabilization. Deposition 
of substances such as MSU crystals, silica crystals, cholesterol crystals, and Aβ, induce NLRP3 
inflammasome activity that leads to inflammatory diseases including gout, silicosis, 
atherosclerosis, and Alzheimer’s disease, respectively (Cassel et al., 2008; Duewell et al., 2010; 
Halle et al., 2008; Martinon et al., 2006; Rajamaki et al., 2010). My research provides evidence 
that lysosomal disruption in RPE cells activates the NLRP3 inflammasome, suggesting that the 
NLRP3 inflammasome may also contribute to the pathogenesis of AMD. 
Although drusen deposition, the accumulation of lipofuscin in RPE lysosomes, and RPE 
lysosomal dysfunction have all been associated with AMD, the nature of their involvement in the 
development of AMD, if any, has remained unclear. Additionally, although mounting evidence 
indicates that inflammation plays a role in the pathogenesis of AMD, the mechanism underlying 
this inflammation has not been determined. The finding that RPE lysosomal destabilization 
activates the NLRP3 inflammasome, resulting in IL-1β release and pyroptotic cell death, points 
to a mechanism by which features associated with AMD, such as drusen or lipofuscin, may lead 
to inflammation and cytotoxicity. 
In addition to my work, there are several other recent reports describing NLRP3 
inflammasome activity in the RPE or in animal models of AMD that corroborate many of my 
findings (Doyle et al., 2012; Marneros, 2013; Tarallo et al., 2012). Collectively, this body of 
research sheds important light on the contribution of the NLRP3 inflammasome to AMD, while 
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raising key questions about the nature and mechanism of that contribution. As there is currently 
no Food and Drug Administration-approved treatment for GA, the advanced form of dry AMD, 
this research may open much-needed avenues for therapeutic intervention. Certain disorders 
mediated by the NLRP3 inflammasome, such as CAPS, are treated using agents that target the 
IL-1 pathway, suggesting that it is possible that such treatments may be effective against GA. 
 
 
Expression of NLRP3 inflammasome components and pro-IL-1β in the RPE 
 
I found that NLRP3 is expressed in the RPE of patients with GA and neovascular AMD, 
but is absent in the RPE of age-matched individuals without AMD. This finding is consistent with 
observations in myeloid-derived cells, which indicate that NLRP3 is often not constitutively 
expressed, but instead requires induction known as priming, which also triggers expression of 
pro-IL-1β (Bauernfeind et al., 2009). Priming can be achieved by a pro-inflammatory stimulus 
that activates NF-κB (Hiscott et al., 1993). For example, the NF-κB agonist LPS is frequently 
used to prime myeloid cells in culture. In contrast to RPE in vivo, I found that cultured RPE cells 
express NLRP3 constitutively, although production of pro-IL-1β required stimulation by a NF-κB-
inducing cytokine such as IL-1α or TNFα. The constitutive expression of NLRP3 by RPE in 
culture, but not in vivo, is likely due to conditions associated with in vitro cell culture such as the 
presence of serum or culture on a plastic substratum.  
Although priming of RPE cells in vitro is achieved by IL-1α and TNFα, and experiments 
involving myeloid cells often utilize LPS as a priming agent, the factor or factors that induce 
NLRP3 and pro-IL-1β expression in vivo remain unclear. However, the observation that NLRP3 
is expressed in the RPE of eyes affected by advanced AMD, but not control eyes without AMD, 
suggests that molecular or cellular changes associated with the development of AMD mediate 
the pathological priming of the RPE. Of the candidate priming agents that I tested, IL-1α was the 
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most effective. It is possible that IL-1α may be released as a result of age-related damage 
associated with AMD. IL-1α is a mediator of sterile inflammation, an inflammatory response 
against stimuli that are not pathogens (Lukens et al., 2012). Cell death, tissue damage, and 
particles or crystals such as MSU can activate a sterile inflammatory response. Like IL-1β, IL-1α 
is synthesized as an intracellular precursor lacking a signal peptide. However, whereas pro-IL-
1β is inactive, pro-IL-1α is biologically active, and its release from necrotic or pyroptotic cells 
induces local inflammation (Kim et al., 2013). Furthermore, various inflammatory cytokines, 
including IL-1α itself, IL-1β, or TNFα, have been shown to stimulate RPE cells to produce the IL-
1α precursor (Jaffe et al., 1992). Death of aged RPE cells may cause the release of IL-1α, 
leading to the priming of RPE cells in the vicinity. 
In addition to IL-1α, TNFα also primes RPE cells in vitro. Macrophage-derived TNFα has 
been reported to contribute to wet AMD, as macrophages present in surgically excised choroidal 
neovascular membranes express TNFα (Oh et al., 1999), and inhibition of TNFα signaling in an 
experimental laser-induced murine model of CNV reduced the size of CNV lesions and the 
extent of permeability (Shi et al., 2006). Furthermore, intravitreal injection of the drusen 
constituent Aβ induces prolonged transcriptional upregulation of TNFα in the neuroretina and 
transient upregulation in the RPE/choroid, suggesting that secretion of TNFα may occur in 
retinas of eyes with drusen (Liu et al., 2013). 
A recent paper demonstrated that CEP-protein adducts can prime myeloid-derived cells 
to express pro-IL-1β (Doyle et al., 2012). CEP-protein adducts are products of oxidation found in 
greater abundance in the outer retinal tissues and sera of AMD patients than normal human 
donors. Induction of inflammasome assembly in bone marrow-derived macrophages via 
treatment with ATP resulted in production of IL-1β when the cells were first primed with HSA 
adducted to CEP, but not HSA alone. It was also shown that CEP-induced priming is mediated 
by TLR2, as macrophages from TLR2-null mice did not produce IL-1β when primed with CEP-
adducted HSA and activated by ATP. In mice, RPE cells have been found to express low levels 
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of TLR2, which is upregulated by exposure to LPS (Fujimoto et al., 2010). Thus, it is possible 
that CEP-protein adducts may prime RPE cells. 
Unlike pro-IL-1β, I detected both ASC and procaspase-1 under basal conditions. 
However, similar to pro-IL-1β, the levels of procaspase-1 were upregulated by priming, whereas 
ASC expression was largely unresponsive to priming. It remains unclear whether the expression 
of procaspase-1 is regulated in vivo as it is in vitro, but it is possible that priming is required for 
procaspase-1 expression in vivo as part of a mechanism to control inflammasome activity in the 
RPE. Based on studies in myeloid cells, it has been hypothesized that two signals are required 
for NLRP3 inflammasome activation, i.e. a priming signal to induce NLRP3 and pro-IL-1β 
expression and an activation signal to trigger inflammasome assembly. This level of control 
presumably exists to ensure that production of IL-1β, a very potent pro-inflammatory cytokine, 
only occurs in response to appropriate stimuli. Since RPE cells are not “professional” immune 
cells, it is possible that they may maintain even stricter control over the expression of 
inflammasome components than myeloid cells, requiring priming not only for expression of pro-
IL-1β and NLRP3, but also upregulation of procaspase-1. This would not only prevent 
unintended activation of the NLRP3 inflammasome, but all of the inflammasomes. 
Interestingly, both RPE cells and myeloid-derived cells such as macrophages are 
capable of phagocytosis. Whereas myeloid cells ingest foreign substances or pathogens, RPE 
cells primarily phagocytose the outer segment discs shed by photoreceptors. This RPE function 
is necessary for the replenishment of the chromophore 11-cis retinal, which is converted to all-
trans retinal upon absorption of a photon (Sparrow et al., 2010). Photoreceptors do not express 
the enzymes necessary to convert all-trans retinal back to 11-cis retinal, whereas RPE cells do. 
Thus, all-trans retinal is transferred to an outer segment disc where it undergoes reduction to 
form all-trans retinol. Upon phagocytosis of the discs by the RPE, the enzymes LRAT, RPE65, 
and 11-cis retinol dehydrogenase convert all-trans retinol to 11-cis retinal, which is subsequently 
returned to the photoreceptor (Sparrow et al., 2010). Disc shedding and phagocytosis are 
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influenced by daily light-dark cycles, with shedding and phagocytosis peaking shortly after the 
onset of light and reaching their lowest levels during darkness (Grace et al., 1999). Since 
phagocytosis is a primary function of both RPE cells and myeloid-derived immune cells, it may 
be that the ability to express NLRP3 is a characteristic of phagocytes. 
 
Activation of the NLRP3 inflammasome in RPE cells by lysosomal destabilization 
 
As the expression of NLRP3 is not sufficient to activate the NLRP3 inflammasome, 
identification of the stimuli that activate the inflammasome in RPE cells is essential to evaluating 
the role that the NLRP3 inflammasome may play in AMD. Lysosomal destabilization has been 
shown to activate the NLRP3 inflammasome in myeloid cells, and I have demonstrated that 
destabilization of RPE lysosomes triggers inflammasome activation. To disrupt RPE lysosomes, 
I utilized the compound Leu-Leu-OMe, which accumulates in lysosomes and is converted to a 
membranolytic derivative by the intralysosomal enzyme DPP-I. Inhibition of DPP-I has allowed 
me to demonstrate that inflammasome activation induced by Leu-Leu-OMe is due to lysosomal 
disruption, rather than off-target effects of the molecule.  
Studies using myeloid cells have indicated that lysosomal destabilization activates 
NLRP3 via a mechanism involving lysosomal proteases, specifically cathepsins B and L 
(Duewell et al., 2010; Halle et al., 2008; Hornung et al., 2008; Rajamaki et al., 2010). Similarly, I 
have found that cathepsin B, and possibly cathepsin L, released by lysosomal membrane 
damage, are responsible for activating the NLRP3 inflammasome. A recent report demonstrated 
that NLRP3 inflammasome activation in glial cells by Aβ involves the degradation of NLRP10 by 
cathepsins B and L (Murphy et al., 2013). NLRP10 is a NLR family member that possesses a 
pyrin domain and a nucleotide-binding domain, but lacks leucine-rich repeats seen in other 
NLRs. NLRP10 negatively regulates inflammasome assembly by binding ASC and preventing 
its recruitment by NLRP3. During NLRP3 inflammasome assembly, NLRP3 recruits ASC 
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molecules and induces their oligomerization into a speck-like structure. NLRP10 antagonizes 
this process by binding ASC and preventing its association with NLRP3. Phagocytosis of Aβ by 
glial cells results in lysosomal destabilization and release of cathepsins B and L into the cytosol, 
where they degrade NLRP10, enabling binding of NLRP3 to ASC and assembly of the 
inflammasome. It is highly likely that lysosomal destabilization activates the NLRP3 
inflammasome through a similar mechanism in RPE cells, either involving degradation of 
NLRP10 or an analogous inhibitory protein. 
 
Drusen and lipofuscin as potential destabilizers of RPE lysosomes 
 
The progression of AMD is thought to involve several sources of RPE lysosomal 
damage, including drusen, BLinD, and lipofuscin. Phagocytosis of isolated drusen deposits or 
drusen components such as the complement component C1Q has been reported to activate the 
NLRP3 inflammasome in myeloid cells (Doyle et al., 2012). In light of the fact that it is the 
insoluble physical nature of insoluble or particulate matter that is responsible for their ability to 
disrupt lysosomes and activate NLRP3, rather than their biochemical activity, it is likely that 
internalization of drusen, BLinD, or their constituents by RPE cells would also induce the NLRP3 
inflammasome.  
A recent study using rats found that intravitreal injection of the drusen constituent Aβ 1-
40 led to the upregulation of genes including IL-1β, IL-18, and NLRP3 in the RPE/choroid (Liu et 
al., 2013). The specificity of this effect was demonstrated by the induction of IL-1β protein in the 
retinas and RPE of rats injected with Aβ 1-40, but not the non-aggregating reverse control 
peptide, Aβ 40-1. Levels of both IL-1β and IL-18 were significantly elevated in the vitreous of Aβ 
1-40-injected rats, compared to their Aβ 40-1-injected counterparts. Consistent with the fact that 
that the cytokines were generated by the RPE, microglial activation was minimal. Despite the 
elevation in cytokine levels, no changes in neuroretinal thickness were noted in animals injected 
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with Aβ 1-40 up to 49 days post-injection, and there was no evidence of neovascularization or 
BrM disruption. The upregulation of NLRP3 and IL-1β observed in the RPE/choroid suggests 
that RPE cells are primed by exposure to Aβ 1-40. Additionally, the detection of IL-1β in the 
neuroretina and RPE, as well as the elevation of IL-1β and IL-18 in the vitreous, suggests that 
Aβ 1-40, and likely other drusen components, can activate the inflammasome in the RPE in 
vivo. One caveat with this study, however, is that it was not demonstrated that the cytokines had 
been processed into their mature forms. Furthermore, although microglial activation was 
minimal, it remains possible that a low level of microglial inflammasome activity could generate 
the cytokine levels observed in the study, rather than or in addition to the RPE. 
It is important to note that the phagocytosis of outer segment discs takes place on the 
apical surface of the RPE, whereas drusen deposits are localized basolaterally. It seems 
unlikely that any phagocytosis occurs on the basolateral surface, as molecules that mediate 
photoreceptor outer segment phagocytosis, such as αvβ5 integrin and Mer tyrosine kinase, have 
an apical localization (Nandrot et al., 2012). It is speculated that drusen deposition is the result, 
at least in part, of exocytosis or transcytosis that occurs when the capacity for lysosomal 
degradation has been exceeded or impaired (Ambati et al., 2013; Krohne et al., 2010). 
Consistent with this notion, exosome marker proteins such as CD63 and LAMP2 have been 
shown to be present in drusen from AMD patients, but not in age-matched control individuals 
(Wang et al., 2009). In rats, reduction of lysosomal degradative ability using chloroquine results 
in the deposition of undegraded phagocytosed photoreceptor outer segments in the space 
between the RPE and BrM (Peters et al., 2006). In a like fashion, modification of proteins with 
the lipid peroxidation products 4-hydroxynonenal and malondialdehyde reduces their 
degradation in RPE lysosomes (Krohne et al., 2010). Modification of photoreceptor outer 
segment proteins with these products, followed by phagocytosis of the outer segments by 
ARPE-19 cells polarized on Transwell membranes, results in the release of undegraded outer 
segment proteins in the basolateral medium. It has been similarly observed in frog RPE that 
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residual products of lysosomal degradation are basolaterally exocytosed and accumulate 
between the RPE and BrM (Rungger-Brandle et al., 1987). Furthermore, presentation of latex 
particles to the apical surfaces of RPE cells leads to their ingestion and subsequent release on 
the basolateral side (Matsumura et al., 1985). These findings suggest that materials found in 
drusen may have originated from RPE lysosomes, with the corollary that drusen deposition 
results from impaired RPE lysosomal function. The presence in RPE lysosomes of molecules 
known to be constituents of drusen and/or the accumulation of undegraded material in 
dysfunctional RPE lysosomes may result in lysosomal membrane disruption and subsequent 
NLRP3 inflammasome activation. Additionally, although drusen accumulate on the basolateral 
surface, reticular pseudodrusen, which are also correlated with AMD progression, occur on the 
apical surface of the RPE and may be phagocytosed. 
Lipofuscin, a pigmented, granular substance of heterogeneous composition consisting of 
the indigestible byproducts of lysosomal degradation, is also a characteristic of AMD. Lipofuscin 
accumulates in a number of cell types, especially postmitotic cells with substantial metabolic 
activity, including cardiac myocytes and some types of neurons (Sparrow and Boulton, 2005). A 
number of the compounds of RPE lipofuscin are derived from molecules present in 
phagocytosed outer segments. One such compound, the bisretinoid fluorophore A2E, is a major 
component of RPE lipofuscin (Schutt et al., 2007). However, the notion that A2E is a component 
of lipofuscin has recently been challenged, based on the finding that it does not colocalize with 
lipofuscin fluorescence in the human RPE (Ablonczy et al., 2013; Smith et al., 2013). If true, 
RPE lipofuscin nonetheless contains a number of bisretinoid molecules with similar chemical 
attributes as A2E, and therefore may have comparable effects on cells (Sparrow et al., 2013). 
A2E has been demonstrated to exhibit detergent-like properties and can destabilize lysosomal 
membranes (Schutt et al., 2002; Sparrow et al., 1999). Accordingly, a recent study reported that 
endocytosis of A2E by ARPE-19 cells in vitro activates the inflammasome, as evidenced by the 
formation of ASC speck-like complexes and the release of IL-1β from IL-1α-primed ARPE-19 
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cells (Anderson et al., 2013). Furthermore, the release of IL-1β from primed RPE cells is 
dependent on caspase-1 activity and is significantly inhibited by blockade of cathepsin B, 
suggesting that A2E-induced inflammasome activation occurs through cathepsin-mediated 
induction of the NLRP3 inflammasome. Thus, lysosomal destabilization represents a 
mechanism through which features associated with AMD may promote AMD pathology. 
 
Effector functions of the NLRP3 inflammasome in AMD 
 
Inflammasomes are capable of a number of effector functions, including the processing 
and release of mature IL-1β and IL-18, as well as caspase-1-mediated programmed cell death, 
or pyroptosis. My work demonstrates that activation of the inflammasome in primed RPE cells 
results in IL-1β maturation and release, as well as pyroptotic cell death. Pyroptosis mediated by 
caspase-1 may lead directly to RPE cell death, contributing to GA, whereas IL-1β may 
contribute to AMD via inflammation. 
It should be noted that the levels of IL-1β released from RPE cells are modest compared 
to those released from myeloid-derived cells (Halle et al., 2008; Hornung et al., 2008). However, 
the inflammation associated with AMD is low-level and chronic in nature, and the relatively low 
levels of IL-1β generated by the RPE are consistent with this fact. The term para-inflammation 
has been used to describe a low-grade inflammatory response that is intermediate between the 
basal state and classic frank inflammation (Medzhitov, 2008). It is hypothesized that both classic 
inflammation and para-inflammation are mechanisms by which the body attempts to restore 
tissue homeostasis. Classic inflammation is a reaction to severe departures from tissue 
homeostasis, such as infection or overt tissue damage, whereas para-inflammation is a 
response to more moderate tissue dysfunction or stress that could result from exposure to 
noxious conditions, such as oxidative stress. Persistence of tissue stress or dysfunction may 
lead to a maladaptive state of chronic para-inflammation. Para-inflammation is believed to 
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contribute to pathological conditions such as atherosclerosis, obesity, type 2 diabetes mellitus, 
and neurodegenerative diseases (Xu et al., 2009). It is suspected that factors such as the age-
related accumulation of oxidative damage in the outer retina, the deposition of drusen, the 
decline in RPE lysosomal degradative function over time, and other age-related retinal changes 
generate outer retinal tissue stress, resulting in chronic para-inflammation that contributes to 
AMD. My findings suggest that NLRP3 inflammasome activity in the RPE may be involved in 
para-inflammation in the outer retina. Lysosomal damage in the RPE, which is a form of tissue 
stress or dysfunction, may trigger the production of low levels of IL-1β via the inflammasome, 
promoting para-inflammation, and ultimately, AMD. 
 
Comparison of NLRP3 inflammasome function in RPE versus myeloid cells 
 
A majority of the studies on inflammasomes have been conducted in myeloid cells so it 
is of interest to identify the commonalities and differences between inflammasome function in 
RPE cells and in myeloid cells. My work indicates that RPE cells, similar to myeloid cells, 
require priming to induce expression of both pro-IL-1β and NLRP3, indicating that the two cell 
types may share signaling mechanisms responsible for upregulating pro-IL-1β and NLRP3. In 
vitro, however, NLRP3 is constitutively expressed in RPE cells, likely due to the effects of 
culture conditions as we did not detect expression in non-diseased cells in vitro. 
Interestingly, my data demonstrated that priming also upregulates the expression of 
procaspase-1 in RPE cells in vitro, but procaspase-1 levels in myeloid cells have not been 
reported to respond to priming. It is important to note that a major function of myeloid cells is 
involvement in innate immunity whereas RPE cells serve a myriad of other essential roles. 
Therefore, it is possible that the requirement of priming for procaspase-1 upregulation may 
prevent unwarranted inflammasome activity in RPE cells. Also, RPE cells cannot be replaced if 
lost due to inflammation or pyroptotic cell death, whereas myeloid-derived cells are continually 
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replenished. Thus, the control of procaspase-1 levels via priming may restrict inflammasome 
activity in RPE cells only to situations where it is necessary, whereas this level of regulation is 
not essential in myeloid cells. That said, induction of procaspase-1 by priming in RPE cells has 
only been demonstrated in vitro, and this finding needs to be validated in vivo. 
Regarding the mechanism of NLRP3 inflammasome activation, my findings support a 
model in which lysosomal destabilization induces NLRP3 inflammasome assembly via 
cathepsins, a mechanism similar to what has been described in myeloid cells (Halle et al., 2008; 
Hornung et al., 2008). However, lysosomal destabilization is only one of several proposed 
mechanisms for NLRP3 inflammasome activation in myeloid cells; others include potassium 
efflux and ROS production, and my results do not preclude the possibility that the other 
mechanisms function in RPE cells as well. In support of this possibility, activation of the NLRP3 
inflammasome in RPE cells by Alu RNA elements has recently been shown to be mediated by 
the purinergic receptor P2X7 (Kerur et al., 2013). P2X7 functions as a ligand-gated cation 
channel that is opened by ATP. In myeloid cells, binding of extracellular ATP to P2X7 results in 
potassium efflux and subsequent induction of NLRP3 inflammasome assembly. The 
involvement of P2X7 in Alu RNA-mediated NLRP3 activation suggests that potassium efflux 
may trigger the NLRP3 inflammasome in RPE cells as well. 
It remains unclear, even in the well-studied context of myeloid cells, how signals as 
distinct as potassium efflux, ROS generation, and lysosomal destabilization induce assembly of 
the NLRP3 inflammasome. It seems likely that these diverse stimuli activate mechanisms that 
feed into a common pathway that is the proximal inducer of NLRP3. It is not clear that all of 
these pathways function in RPE cells. It has recently been reported that oxidative stress 
induced by hydrogen peroxide or tert-butyl hydroperoxide causes ARPE-19 cells to undergo 
necrotic cell death, without triggering apoptosis or pyroptosis (Hanus et al., 2013). In these 
studies caspase-1 was not activated by treatment with hydrogen peroxide or tert-butyl 
hydroperoxide, suggesting that the ROS pathway of NLRP3 activation does not function in RPE 
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cells as it does in myeloid cells. Further research is warranted to evaluate the similarities and 
differences between the inflammasome priming and activation pathways in RPE cells and those 
in myeloid cells. Figure 11 illustrates the findings presented in this dissertation with those 
described in the literature for RPE and myeloid cells. 
 
Involvement of the NLRP3 inflammasome in animal models of AMD 
 
Recently, several studies have evaluated the contribution of the NLRP3 inflammasome 
to AMD-like pathology in mice. Importantly, modeling AMD in mice is problematic as mice lack a 
macula and therefore do not develop true AMD. Furthermore, mice are short-lived with an 
average lifespan of two years, and therefore the development of age-related pathology requires 
experimental manipulation that is unlikely to accurately reflect the temporal mechanism of the 
disease. Nonetheless, mice are receptive to genetic manipulations such as gene knockout, 
making them useful, albeit imperfect, model organisms for the study of AMD. 
One study utilized mice with RPE-specific deletion of DICER1, which was demonstrated 
to lead to the intracellular accumulation of noncoding RNA transcripts expressed by the Alu 
retrotransposon (Tarallo et al., 2012). This accumulation of Alu transcripts in RPE results in 
degeneration mediated by the NLRP3 inflammasome and IL-18, but not by IL-1β. Deficiency in 
NLRP3, ASC, Casp1, or IL18 prevents Alu-induced RPE degeneration, whereas the absence of 
IL1R1, the receptor that mediates IL-1β signaling, does not. The authors hypothesize that 
activation of the NLRP3 inflammasome in RPE cells by Alu RNA generates mature IL-18, which 
induces the RPE degeneration observed in GA. A subsequent study from the same group found 
that Alu RNAs prime RPE cells via TLR-independent NF-κB induction and activate the NLRP3 
inflammasome via the P2X7 receptor, a ligand-gated cation channel that responds to 
extracellular ATP, another NLRP3 agonist (Kerur et al., 2013). Binding of ATP to P2X7 triggers 
potassium efflux, which in turn activates NLRP3 through an incompletely characterized  
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Figure 11. Schematic comparing NLRP3 inflammasome priming and activation in RPE 
and myeloid cells. (A) Priming signals induce upregulation of inflammasome-related proteins in 
myeloid cells and RPE cells. Previous research has determined that priming induces expression 
of pro-IL-1β and NLRP3 in myeloid cells. My findings indicate that priming RPE cells induces 
upregulation of procaspase-1, in addition to pro-IL-1β and NLRP3. (B) Activation of the NLRP3 
inflammasome in myeloid cells has been demonstrated to occur in response to lysosomal 
destabilization, potassium efflux, and ROS production. My work shows that the NLRP3 
inflammasome is activated by lysosomal destabilization in RPE cells. Other research has 
indicated that accumulation of Alu RNA transcripts in RPE cells also triggers NLRP3 
inflammasome assembly, and it has not yet been determined whether this mode of NLRP3 
activation functions in myeloid cells. 
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mechanism (Mariathasan et al., 2006; Schroder and Tschopp, 2010). It is likely that Alu 
transcripts activate NLRP3 through a similar mechanism, rather than through lysosomal 
destabilization, which occurs independently of P2X7. 
Whereas the latter study suggested that NLRP3 inflammasome activity in RPE cells 
might contribute to GA via IL-18, another group reported substantially different results. Using a 
model in which dry AMD-like pathology is induced by immunization of mice with CEP adducted 
to MSA, infiltrating macrophages in the retinas of mice were shown to stain for cleaved 
caspase-1, indicating inflammasome activation (Hollyfield et al., 2008). Furthermore, in a laser 
injury-induced mouse model of CNV, deletion of NLRP3 or IL18 exacerbated the 
neovascularization compared to wild-type mice, suggesting that these genes play a protective 
role against CNV (Doyle et al., 2012). On the other hand, deletion of IL1R1 resulted in a trend 
toward reduction of CNV lesion volume compared to wild-type that did not reach statistical 
significance. Thus, the authors of this study hypothesize that macrophages are the primary 
source of NLRP3 inflammasome activity in AMD, and that NLRP3-mediated IL-18 release is 
protective against CNV. This suggestion is in direct contrast to the findings from the Alu-induced 
model, in which IL-18 generated via NLRP3 inflammasome activity contributed to RPE 
degeneration. These apparently conflicting results may due to the possibility that the NLRP3 
inflammasome plays different roles in dry and wet AMD. However, it is important to note that the 
laser injury model of CNV is not fully representative of the neovascularization observed in wet 
AMD. Laser-induced CNV is more appropriately regarded as a model of acute wound healing 
that takes place in the presence of otherwise healthy RPE cells that likely are not primed to 
express NLRP3 (Marneros, 2013). Thus, given the previously reported role of the NLRP3 
inflammasome in promoting epithelial repair via IL-18 (Dupaul-Chicoine et al., 2010; Zaki et al., 
2010), it is reasonable to suspect that the function of the NLRP3 inflammasome in an acute 
wound-healing model does not reflect its role in AMD. That said, it could also be argued that Alu 
RNA transcript accumulation may not recapitulate the mechanism of dry AMD. 
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Another recent report utilizes a mouse model in which expression of vascular endothelial 
growth factor-A (VEGF-A) is heightened (VEGF-Ahyper) resulting in RPE abnormalities including 
loss of tight junctions (Marneros, 2013). Examination of the retinas of VEGF-Ahyper mice up to 24 
months of age reveals progressive, age-associated RPE degeneration and concomitant 
photoreceptor degeneration. Sub-RPE deposits reminiscent of human dry AMD pathology were 
also noted, and these mice develop CNV at sites of RPE atrophy. Thus, this mouse model 
appears to mimic pathological features of both dry and wet AMD. Notably, the RPE of VEGF-
Ahyper mice exhibit increased expression of NLRP3 and IL-1β, and the cleaved subunits of 
caspase-1 are detectable in the RPE/choroid, indicating inflammasome activation. Interestingly, 
deletion of NLRP3, IL1R1, or IL18 did not inhibit the RPE degeneration observed in VEGF-Ahyper 
mice and did not prevent the development of CNV. However, CNV lesion numbers are reduced 
in VEGF-Ahyper mice deficient in NLRP3 or IL-1R, indicating that NLRP3 and IL-1β may 
contribute to CNV. Conversely, the absence of IL-18 results in a borderline significant increase 
in CNV lesions, suggesting a protective role for IL-18 in wet AMD. Once again, these 
conclusions must be interpreted with caution; although the VEGF-Ahyper model recapitulates a 
number of pathological features of AMD, there is no evidence that the underlying mechanism of 
this model accurately reflects the mechanisms of dry and wet AMD. 
 
Future directions 
 
AMD is a complex disease whose etiology remains elusive. Numerous factors are 
associated with AMD, such as the presence of drusen, BLinD, reticular pseudodrusen, and 
lipofuscin, but it is unclear if they are causative. Several lines of evidence, such as the presence 
of proinflammatory molecules in drusen and the link between CFH polymorphisms and AMD 
progression, imply a role for inflammation in the pathogenesis of AMD, but are nonetheless 
correlative. My findings suggest a mechanism that connects AMD-related RPE dysfunction, 
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involving lysosomal damage and exposure to proinflammatory molecules, with outer retinal 
inflammation and ultimately RPE degeneration via the NLRP3 inflammasome. Additional 
research is necessary to further evaluate this mechanism on a biochemical level in vitro, identify 
AMD-related molecules or deposits capable of priming or activating the NLRP3 inflammasome, 
and assess the role of the NLRP3 inflammasome in animal models of AMD-like pathology. 
 
Biochemical characterization of the NLRP3 inflammasome pathway in RPE cells 
Activation of the NLRP3 inflammasome is still incompletely understood in myeloid-
derived cells, and even less is known about its induction in the RPE. The mechanisms that 
regulate the NLRP3 inflammasome in the RPE may differ from those in hematopoietic cells. 
Proteins involved in NLRP3 activation in myeloid cells may have analogous molecules in RPE 
cells, or the molecular pathways may be dramatically dissimilar. Therefore, it will be important to 
elucidate the biochemical mechanism of NLRP3 inflammasome activation in RPE cells. A 
convenient starting point would be to determine whether degradation of NLRP10 by cathepsins 
facilitates recruitment of ASC by NLRP3, as has been demonstrated in glial cells (Murphy et al., 
2013). Additionally, potassium ion efflux and ROS generation have been found to induce the 
NLRP3 inflammasome in hematopoietic cells through mechanisms that appear to be 
independent of lysosomes. It would be of interest to determine whether NLRP3 can be induced 
in RPE cells by these stimuli. 
 
Evaluation of NLRP3 inflammasome priming and activation by AMD-related insults 
My findings have demonstrated that NF-κB agonists prime RPE cells, and that disrupting 
RPE lysosomes induces the NLRP3 inflammasome. However, it is not clear which molecular 
insults or changes associated with AMD, such as accumulation of drusen and other deposits, 
buildup of lipofuscin, AGE generation, and impairment of lysosomal degradative function, are 
capable of priming RPE cells or sufficiently damaging the integrity of the lysosomal membrane 
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to activate NLRP3. A2E has recently been demonstrated to induce IL-1β secretion from RPE 
cells via NLRP3 (Anderson et al., 2013), but the role of A2E as a lipofuscin constituent has been 
called into question (Ablonczy et al., 2013). CEP-protein adducts have been shown to prime 
myeloid cells (Doyle et al., 2012), but their effect on RPE cells has not been tested. Similarly, 
isolated drusen and individual drusen components such as Aβ and complement component 
C1Q have been found to activate the NLRP3 inflammasome in myeloid cells, but have not been 
evaluated in RPE cells (Doyle et al., 2012; Halle et al., 2008). It would be worthwhile to evaluate 
isolated drusen, individual drusen constituents, lipofuscin bisretinoids, CEP-protein adducts, and 
AGEs for their ability to prime or activate the NLRP3 inflammasome in RPE cells. 
 
Assessment of the role of the NLRP3 inflammasome in murine models of AMD-like pathology 
To demonstrate that the NLRP3 inflammasome mediates AMD pathogenesis in 
response to RPE lysosomal destabilization, it will be necessary to develop a mouse model of 
AMD-like retinal pathology induced by RPE lysosomal damage. This may be accomplished via 
subretinal injection of Leu-Leu-OMe or other lysosomotropic compounds, such as chloroquine 
or tamoxifen. To this end, I have conducted studies that demonstrate that tamoxifen induces 
RPE cell death via release of cathepsins B and L, suggesting that subretinal injection of 
tamoxifen may be a viable approach for modeling AMD-like pathology in mice. My work on 
tamoxifen-induced RPE cytotoxicity has been submitted for publication and is currently under 
review. The submitted manuscript is included in the Appendix of this dissertation. Once a 
suitable mouse model has been established, it will be important to evaluate the effects of this 
treatment on mice deficient in Nlrp3, Asc, or Casp1 and compare their retinal pathology with that 
of wild-type mice. 
 
Therapeutic implications 
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Whereas VEGF inhibitors are approved for neovascular AMD, there is currently no 
approved treatment for GA. However, the long-term safety profiles of VEGF inhibitors are just 
beginning to be revealed, and chronic inhibition of VEGF may have unanticipated side effects 
due to its role as a neuroprotectant for photoreceptors and as a survival factor for Muller cells, 
fenestrated vascular endothelium, and RPE (Ford et al., 2011; Saint-Geniez et al., 2009; Saint-
Geniez et al., 2008). Thus, treatment options for AMD that target the NLRP3 inflammasome are 
likely to be of great benefit. Several biologic agents that target the IL-1 pathway are approved 
for use by the Food and Drug Administration. Anakinra, a recombinant IL-1 receptor antagonist, 
has been approved for treatment of rheumatoid arthritis, and the monoclonal anti-IL-1β antibody 
canakinumab and the “IL-1 trap” fusion protein rilonacept are approved for treatment of CAPS 
(Lachmann et al., 2011; Mitroulis et al., 2010). However, the potential role of the NLRP3 
inflammasome in the pathogenesis of AMD, as well as the downstream cytokines involved, must 
be elucidated in order to determine whether targeting the IL-1 pathway will be effective. 
 
Concluding remarks 
 
As the American population continues to age, it is projected that nearly three million 
individuals will be affected by AMD by the year 2020 (Friedman et al., 2004). A more complete 
understanding of the mechanisms underlying AMD pathogenesis is essential if this growing 
public health challenge is to be addressed. The discovery that the NLRP3 inflammasome 
functions in RPE cells and can mediate IL-1β release from RPE cells is a key finding that may 
generate new therapeutic targets for AMD. However, research on inflammasomes in AMD 
remains nascent, and many questions remain regarding the role that the NLRP3 inflammasome 
plays in AMD. This uncertainty stems, at least in part, from the lack of accurate animal models 
of AMD. Nevertheless, the finding that the RPE lysosomal destabilization activates the NLRP3 
inflammasome provides a mechanistic link between the classic features of AMD, drusen and 
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lipofuscin, and the inflammation and cytotoxicity that appear to contribute to RPE degeneration. 
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CHAPTER 5 
 
 
 
MATERIALS AND METHODS 
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Immunohistochemistry of human retina 
 
De-identified specimens from AMD and control human subjects were obtained from a 
tissue repository established in one of our laboratories at Schepens Eye Research Institute 
under IRB approval. Specimens were fixed in 10% buffered formalin, embedded in paraffin, and 
sectioned. For immunohistochemistry, sections were deparaffinized and antigen retrieval was 
performed with citrate buffer (10 mM citric acid, 0.05% Tween-20, pH 6.0, 95-100°C) for 10 
minutes. Following two washes in phosphate buffered saline (PBS; Sigma-Aldrich, St. Louis, 
MO), slides were incubated with a mouse monoclonal anti-human NLRP3 antibody (1:100; 
clone Nalpy3-b; Enzo Life Sciences, Farmingdale, NY) or a mouse IgG1 isotype control 
antibody (1:100; Caltag, Carlsbad, CA) overnight at 4°C. The secondary antibody, a biotinylated 
horse anti-mouse IgG (1:200, Vector Laboratories, Burlingame, CA), was visualized via the 
avidin-biotin-alkaline phosphatase complex (ABC-AP) method (Vectastain ABC-AP Kit; Vector 
Laboratories) using the Vector Red Substrate (Vector Laboratories). Slides were counterstained 
with hematoxylin, dehydrated, and mounted with Permount medium (Fisher Scientific, 
Pittsburgh, PA). 
 
RPE cell culture 
 
Human ARPE-19 cells (American Type Culture Collection, Manassas, VA) were 
propagated as described previously (Ford et al., 2011). Cells were cultured in DMEM/F12 
medium (Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum (FBS; Atlanta 
Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Lonza), and 100 U/ml penicillin-100 µg/ml 
streptomycin (Lonza) (complete ARPE-19 medium) and passaged at a ratio of 1:2 to 1:4 using 
trypsin-EDTA (Life Technologies, Carlsbad, CA, or Lonza). For experiments, ARPE-19 cells 
were maintained in either 1% FBS or serum-free ARPE-19 medium, and transfections were 
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performed in antibiotic-free ARPE-19 medium. 
Primary human fetal RPE (hfRPE) cells (Lonza) were propagated in Retinal Pigment 
Epithelial Cell Basal Medium (Lonza) supplemented with 5% FBS, 2 mM L-glutamine, and 100 
U/ml penicillin-100 µg/ml streptomycin (complete hfRPE medium). At confluence, hfRPE cells 
were passaged at a ratio of 1:2 to 1:4 using trypsin-EDTA (Life Technologies or Lonza). For 
experiments, hfRPE cells were seeded at passage 6-8 and were maintained in serum-free 
hfRPE medium. 
 
Immunocytochemistry 
 
ARPE-19 cells were cultured on Transwell membranes for four weeks in ARPE-19 
medium with 1% FBS, as described elsewhere (Ford et al., 2011), to induce RPE polarization 
and tight junction formation. Monolayers were fixed in 4% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA), and then incubated with a mouse monoclonal anti-human 
NLRP3 primary antibody (1:100; clone Nalpy3-b; Enzo Life Sciences) or a mouse IgG isotype 
control antibody (1:100; Life Technologies) overnight at 4°C. The secondary antibody, a 
biotinylated horse anti-mouse IgG (1:200, Vector Laboratories, Burlingame, CA), was visualized 
via the ABC-AP method (Vector Laboratories) using the Vector Red Substrate (Vector 
Laboratories). Nuclei were labeled with DAPI. Transwell membranes with attached monolayers 
were excised from their supports and mounted on glass slides for confocal microscopy (Leica 
Microsystems; Wetzlar, Germany). 
 
Priming of ARPE-19 cells with NF-κB-inducing agents 
 
 ARPE-19 cells were seeded into 12-well plates (BD Biosciences, San Jose, CA) at a 
density of 2.6 x 105 cells/well in complete ARPE-19 medium. At confluence, the culture medium 
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was changed to serum-free medium and cells were treated with ultra-pure LPS from Escherichia 
coli 0111:B4 strain (InvivoGen, San Diego, CA), recombinant human IL-1α (R&D Systems, 
Minneapolis, MN), or recombinant human TNFα (PeproTech, Rocky Hill, NJ). Each agent was 
tested at 4 ng/ml or 50 ng/ml for 24 hours or 48 hours. Whole cell lysates were immunoblotted 
for pro-IL-1β. 
 
NLRP3 knockdown 
 
ARPE-19 cells were grown as described above and seeded into 6-well plates (BD 
Biosciences) at a density of 1.5 x 105 cells/well in antibiotic-free ARPE-19 medium. The 
following day, at approximately 40% confluence, cells were transfected with ON-TARGETplus 
SMARTpool siRNA against human NLRP3 or a non-targeting control SMARTpool (Dharmacon, 
Lafayette, CO). The target sequences of the siRNAs in each pool are provided in Table 1. The 
control siRNA pool was transfected at a total siRNA concentration of 100 nM using 
DharmaFECT 4 (Dharmacon), and the NLRP3 siRNA pool was used at 50 nM and 100 nM. At 
24 hours post-transfection, cells were washed once with PBS, and complete ARPE-19 medium 
containing 4 ng/ml IL-1α was added to the wells to prime the cells. Cells were lysed at 72 hours 
post-transfection and immunoblotted for NLRP3. 
 
NLRP3 overexpression and immunoblotting 
 
To generate a positive control for NLRP3, lysates of HEK293T cells overexpressing the 
full-length transcript variant of NLRP3 fused to a DDK tag (identical to FLAG tag) and myc tag or 
transfected with a mock vector were purchased from OriGene (Rockville, MD). Immunoblotting 
for NLRP3 was performed on lysates of ARPE-19 and THP-1 cells, using the NLRP3- and 
mock-transfected HEK293T lysates as controls. Blotting for NLRP3 was followed by stripping 
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and re-probing first for α-tubulin and secondly for DDK. 
 
Effect of priming on expression of pro-IL-1β and inflammasome components by ARPE-19 
cells 
 
ARPE-19 cells were seeded into 6-well plates at a density of 4.0 x 105 cells/well in 
complete ARPE-19 medium. At confluence, the cells were switched to serum-free ARPE-19 
medium. The cells were primed with recombinant human IL-1α. For the dose curve, IL-1α was 
added to cells at concentrations of 1.56, 3.13, 6.25, 12.5, and 25 ng/ml IL-1α and incubated for 
48 hours. For the time course, 4 ng/ml IL-1α was added to wells, and cells were lysed after 3, 6, 
12, 24 or 48 hours. Cells were washed with ice-cold PBS, lysed, and immunoblotted for pro-IL-
1β, NLRP3, ASC, and caspase-1. 
 
Evaluation of hfRPE priming by IL-1α and LPS 
 
hfRPE cells were seeded into 12-well plates at a density of 1.5 x 105 cells/well in 
complete hfRPE medium. Upon reaching confluence, the cells were switched to serum-free 
hfRPE medium containing IL-1α at concentrations of 3, 10, 30, or 100 ng/ml. Negative control 
cells received serum-free medium alone, and some cells were treated with 100 ng/ml ultra-pure 
LPS instead of IL-1α. After 24 hours, cells were washed with ice-cold PBS, lysed, and 
immunoblotted for pro-IL-1β and NLRP3. 
 
Acridine orange staining of RPE lysosomes 
 
ARPE-19 cells were seeded on sterile coverslips placed in a 6-well plate at a density of 
3.0 x 105 cells/well in complete medium. The following day, cells were incubated with complete 
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medium containing 5 µM acridine orange for 30 minutes. Cells were washed twice with PBS, 
then treated with 1 mM Leu-Leu-OMe (Chem-Impex International, Wood Dale, IL, or Santa Cruz 
Biotechnology, Dallas, Texas) or control buffer for 30-45 minutes. Cells were then fixed with 4% 
paraformaldehyde for 30 minutes and washed three times with PBS. Coverslips were then 
mounted on glass slides using Vectashield Mounting Medium for Fluorescence (Vector 
Laboratories) and imaged on an Axioskop 2 mot plus fluorescent microscope (Carl Zeiss, 
Thornwood, NY). 
 
Fluorescent detection of active caspase-1 
 
ARPE-19 cells were seeded into 24-well plates (BD Biosciences) at a density of 5.0 x 
104 cells/well in complete ARPE-19 medium, grown to confluence, and then changed to serum-
free ARPE-19 medium with 4 ng/ml IL-1α. After 48 hours, the cells were pre-treated with the 
dipeptidyl peptidase I inhibitor Gly-Phe-CHN2 (MP Biomedicals, Solon, OH) at a concentration of 
10 µM, the cathepsin B and L inhibitor Z-FF-FMK (EMD Biosciences, San Diego, CA) at a 
concentration of 50 µM, or an equal volume of DMSO vehicle. After 30 minutes, the fluorescent 
labeled inhibitor of caspases (FLICA) probe specific for caspase-1 (FAM-YVAD-FMK; 
Immunochemistry Technologies, Bloomington, MN) was added to each well at the concentration 
recommended by the manufacturer, followed by the addition of 1 mM Leu-Leu-OMe. After a 
two-hour incubation at 37°C, 5% CO2, cell nuclei were stained with Hoechst 33342 
(Immunochemistry Technologies). After washing and fixing cells using wash buffer and fixative 
supplied by the manufacturer, cells were imaged via fluorescence microscopy. 
For hfRPE cells, 48-well plates (BD Biosciences) were seeded at a density of 3.5 x 104 
cells/well in complete hfRPE medium. At confluence, the cells were switched to serum-free 
hfRPE medium with or without 10 ng/ml IL-1α. After 24 hours, cells were treated with FAM-
YVAD-FMK at the recommended dilution, followed by the addition of 1 mM Leu-Leu-OMe to 
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appropriate wells. Cells were incubated for two hours at 37°C, 5% CO2, at which point cell 
nuclei were stained using Hoechst 33342. Cells were washed, fixed, and imaged by 
fluorescence microscopy. 
For analysis of caspase-1 activation in polarized RPE monolayers, hfRPE cells were 
seeded onto 12-mm polyester Transwell membranes with 0.4 µm pores (Corning Incorporated, 
Tewksbury, MA) coated with 10 µg/ml laminin (Sigma-Aldrich). Cells were maintained in serum-
free hfRPE medium, replenished twice weekly, for at least four weeks to allow them to form a 
polarized monolayer. The cells were then treated with serum-free medium with or without 10 
ng/ml IL-1α. Following a 24-hour incubation, FAM-YVAD-FMK was added to all Transwells at 
the recommended dilution, and 1 mM Leu-Leu-OMe was added to appropriate wells. After a 
two-hour incubation at 37°C, 5% CO2, cells were washed with buffer supplied by the 
manufacturer, then fixed with 4% paraformaldehyde for 30 minutes and washed three times with 
PBS. Transwell membranes were excised from their inserts and mounted on glass slides using 
ProLong Gold antifade reagent with DAPI (Life Technologies) and covered with a coverslip. 
Cells were then imaged via fluorescence microscopy. 
ARPE-19 and hfRPE cells on plastic wells were imaged using a Nikon Eclipse TE2000-S 
microscope (Melville, NY). hfRPE cells on mounted Transwells were imaged with an Axioskop 2 
mot plus fluorescent microscope. Quantification of green FLICA signal was performed using 
Adobe Photoshop. Blue nuclei in each image were counted manually, and the amount of green 
signal was normalized to the number of nuclei. 
 
Immunoblotting for mature IL-1β  in concentrated conditioned media 
 
ARPE-19 cells grown to confluence in T75 flasks were primed with 15 ng/ml IL-1α for 48 
hours, then treated with 1 mM Leu-Leu-OMe or control buffer for three hours. Conditioned 
media were harvested and concentrated using 15-ml Amicon centrifugal filter units (Millipore, 
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Billerica, MA) by spinning in an Avanti J-25I centrifuge (Beckman Coulter, Indianapolis, IN) 
using a JA25.50 rotor (Beckman Coulter) at 5,000 x g for one hour at room temperature. 
Following concentration, conditioned media were immunoblotted for IL-1β alongside a standard 
dilution of 0, 25, 50, 100, and 200 pg of recombinant human mature IL-1β (National Cancer 
Institute, Rockville, MD) as positive control. Goat anti-IL-1β (R&D Systems) was used as 
primary antibody at a 1:200 dilution, and HRP-linked rabbit anti-goat IgG (Santa Cruz) 
secondary antibody was used at a 1:5000 dilution. 
 
Evaluation of inflammasome activation by lysosomal disruption 
 
ARPE-19 cells were seeded onto 12-well plates at a density of 1.0 x 105 cells/well in 
complete ARPE-19 medium, grown to confluence and then changed to serum-free ARPE-19 
medium with 4 ng/ml IL-1α. After 48 hr, Gly-Phe-CHN2 (5 µM), Z-FF-FMK (50 µM), the caspase-
1 inhibitor Z-YVAD-FMK (10 µM; BioVision, Mountain View, CA), or DMSO vehicle were added. 
After 30 minutes, 1 mM Leu-Leu-OMe was added to appropriate cells. Conditioned media were 
collected after three hours to assess cytokine secretion and lytic cell death. 
For hfRPE cells, 12-well plates were seeded at a density of 1.5 x 105 cells/well in 
complete hfRPE medium. At confluence, the cells were changed to serum-free hfRPE medium 
with or without 10 ng/ml IL-1α. After 24 hours, cells were pre-treated with Gly-Phe-CHN2 (10 
µM), Z-FF-FMK (50 µM), the selective cathepsin B inhibitor CA-074-Me (50 µM; EMD 
Biosciences), or DMSO vehicle for 30 minutes. Then, 1 mM Leu-Leu-OMe was added to 
appropriate wells. After incubating at 37°C, 5% CO2 for 3 hours, conditioned media were 
collected. 
 
Quantification of cytokine secretion and cytotoxicity 
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ELISA was used to quantify IL-1β (BD Biosciences) and IL-18 (R&D Systems), and 
cytotoxicity was assessed by measuring the levels of lactate dehydrogenase (LDH) in 
conditioned media using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, 
Madison, WI). Each experimental condition was assayed in triplicate in three independent 
experiments. Percent LDH release was calculated as 100% × (experimental LDH − 
spontaneous LDH) / (maximum LDH − spontaneous LDH). Maximum LDH was represented by 
the LDH levels in wells completely lysed by two freeze-thaw cycles. 
 
Immunoblot analysis of whole cell lysates 
 
Cells were treated with lysis buffer (Cell Signaling Technology, Danvers, MA) containing 
a dissolved Complete Mini EDTA-free Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, 
IN) and 2 mM PMSF. Protein concentrations were measured via the BCA assay (Thermo 
Scientific, Waltham, MA). Equal quantities of protein were separated via SDS-PAGE under 
reducing conditions and transferred to PVDF membranes (Millipore). Membranes were blocked 
overnight at 4°C. NLRP3 blots were blocked in Tris-buffered saline with 0.1% Tween (TBS-T) 
containing 5% (w/v) milk and 0.5% (w/v) bovine serum albumin (BSA); all other blots were 
blocked in 5% milk in TBS-T. 
Membranes were then incubated in primary antibody diluted 1:1,000 in their respective 
blocking solution for two hours at room temperature. Primary antibodies used were mouse anti-
NLRP3 (Nalpy3-b, Enzo Life Sciences), rabbit anti-caspase-1 (Cell Signaling), goat anti-IL-1β 
(R&D Systems), and rabbit anti-ASC (Enzo Life Sciences). The caspase-1 and IL-1β antibodies 
also recognize their uncleaved precursors. After three 10-minute washes in TBS-T, membranes 
were incubated for 1 hour at room temperature in secondary antibody diluted 1:10,000 in 
blocking buffer. HRP-linked secondary antibodies included sheep anti-mouse IgG (GE 
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Healthcare), donkey anti-rabbit IgG (GE Healthcare), and donkey anti-goat IgG (Santa Cruz). 
Following four more washes in TBS-T, proteins were visualized by enhanced 
chemiluminescence using SuperSignal substrates (Thermo Scientific). Membranes were 
stripped by incubation in 62.5 mM Tris-HCl (pH 6.8), 2% (w/v) sodium dodecyl sulfate (SDS), 
and 0.1 M β-mercaptoethanol for 30 minutes at 55-60°C; re-blocked overnight at 4°C in 5% BSA 
in TBS-T; and re-probed with rabbit anti-GAPDH (Santa Cruz) to evaluate loading. NLRP3 blots 
were re-probed with mouse anti-α-tubulin (EMD Biosciences). To detect DDK-tagged NLRP3, 
blots were re-probed using mouse anti-DDK tag (OriGene). 
 
Statistical analysis 
 
Data are presented as the mean ± SEM of three independent experiments, unless 
otherwise indicated. To evaluate statistical significance, one-way analysis of variance was 
performed, followed by the Tukey-Kramer multiple comparisons test using the Prism 4 software 
package (GraphPad). A P-value of <0.05 was considered statistically significant. 
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ABSTRACT 
Purpose.  To evaluate the mechanism of tamoxifen-induced cell death in human cultured retinal 
pigment epithelial cells (RPE), and to investigate the relative contribution of cell death 
mechanisms including apoptosis, necroptosis, and pyroptosis. 
 
Methods.   Human RPE cells (ARPE-19 cells) were cultured until confluence and treated with 
tamoxifen; subsequent cell death was measured by detecting lactate dehydrogenase (LDH) 
release.  Lysosomal membrane permeabilization was assessed using acridine orange staining.  
The roles of lysosomal enzymes cathepsin B and L were examined by blocking their activity.  
Caspase activity was evaluated by caspase-1, -3, -8, and -9 specific inhibition.  Cells were 
primed with IL-1α and treated with tamoxifen and IL-1β production was quantified via ELISA.  
Caspase activity was verified with the fluorochrome-labeled inhibitor of caspases (FLICA) probe 
specific for each caspase.  Necroptosis was evaluated using necrostatin-1 (Nec-1) to inhibit 
RIP1 kinase. 
 
Results. Cell death occurred within two hours of tamoxifen treatment of confluent ARPE-19 
cells, and was accompanied by lysosomal membrane permeabilization.  Toxicity was shown to 
occur through both caspase-dependent and non-caspase-dependent cell death pathways.  
Blockage of cathepsin activity resulted in a significant decrease in cell death, indicating that 
lysosomal destabilization and cathepsin release are upstream of these cell death pathways. 
Treatment of ARPE-19 cells with caspase inhibitors and Nec-1 resulted in a near complete 
rescue from cell death.  
 
Conclusions.  Tamoxifen-induced cell death occurs through concurrent cell death mechanisms. 
Simultaneous inhibition of caspase-dependent and caspase-independent cell death pathways is 
	  123	  
required to protect cells from tamoxifen.  Inhibition of upstream activators such as the 
cathepsins may be a feasible approach to block multiple cell death pathways. 
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INTRODUCTION  
Tamoxifen, a non-steroidal estrogen receptor antagonist, has been widely used in low dosages 
for the duration of five years as an adjuvant therapy for some forms of breast cancer. Although 
the current standard of care is five years of tamoxifen therapy, the global Adjuvant Tamoxifen: 
Longer Against Shorter (ATLAS) trial recently showed that 10 years of tamoxifen reduced the 
risk of breast cancer recurrence, reduced breast cancer mortality, and reduced overall mortality. 
1 Thus, it is likely that the standard of care will change, resulting in a longer period of tamoxifen 
therapy with a likely increase in tamoxifen-induced ocular toxicity. 
Tamoxifen can lead to corneal toxicity, progression of cataracts, retinopathy, and 
neuropathy.  The reported incidence of ocular toxic side effects among patients receiving 
tamoxifen ranges from 6.3% to 12%. The most visually significant aspect of tamoxifen toxicity is 
a maculopathy.2 Tamoxifen is structurally similar to other drugs with well-known retinal effects 
including chloroquine, chlorpromazine, thioridazine, and tilorone. Although the RPE is thought to 
be the primary target of tamoxifen toxicity, recent reports have demonstrated that tamoxifen 
toxicity also affects photoreceptors as well. 3 Ultrastructural lesions associated with these 
agents may appear as crystalloid inclusions in the neuroretina or as crystalloid bodies within the 
RPE, which are thought to disrupt lysosomal function. RPE cells serve a critical role in the 
maintenance of photoreceptors, phagocytizing the outer segment tips of photoreceptors, which 
are then digested within lysosomes.  RPE dysfunction is thought to play a role in a variety of 
retinal diseases including age-related macular degeneration (AMD), tamoxifen retinopathy, 
chloroquine retinopathy, central serous retinopathy, as well as a variety of inherited retinal 
disorders. 
 Inflammasomes are a class of multiprotein complexes that activate caspase-1 by 
facilitating the cleavage of procaspase-1 to active caspase-1, which induces the proteolytic 
maturation of the pro-inflammatory cytokines IL-1β and IL-18.  The NLRP3 inflammasome can 
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be activated by a diverse array of signals. 4 Many of these signals activate NLRP3 by 
destabilizing lysosomes.  Crystalline or insoluble materials such as cholesterol crystals and 
amyloid-β can activate NLRP3 in phagocytic myeloid-derived cells by disrupting 
phagolysosomes. 5-8 It has recently been demonstrated that the RPE express components of 
the NLRP3 inflammasome, which plays a role in animal models of AMD through lysosomal 
destabilization or accumulation of Alu RNA due to DICER1 deficiency in the RPE. 9, 10  We 
hypothesize that medications such as tamoxifen can disrupt lysosomal membranes, leading to 
the activation of the NLRP3 inflammasome, release of the pro-inflammatory cytokine IL-1β, and 
pyroptosis.11 
 Necroptosis is characterized by the activation of RIP-1 and RIP-3 kinase and is triggered 
by a variety of stimuli including TNF, DNA damage, and viral infection. 12-15 Cellular components 
or endogenous adjuvants such as high mobility group protein B1, uric acid, galectins, and 
thioredoxin released as a consequence of cellular demise promote an inflammatory response 
with activation of inflammasomes, cytokine production, inflammatory cell recruitment, and T-cell 
activation.16 Necroptosis has been defined as caspase-independent cell death with a necrotic 
phenotype that can be prevented by the specific RIP1 inhibitor necrostatin-1 (Nec-1). 17, 18  
Necroptosis has been demonstrated to occur in T lymphocytes, photoreceptors, astrocytes, and 
neurons and has been suggested to be involved in myocardial infarction.19-23 
 Here, we report on the involvement of multiple cell death mechanisms in tamoxifen-
induced toxicity of the RPE.  Specifically, we examined the roles of inflammasome-mediated cell 
death, the extrinsic and intrinsic pathway of apoptosis, and RIP kinase-mediated necroptosis. 
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MATERIALS AND METHODS 
ARPE-19 Cell Culture 
Human ARPE-19 cells (American Type Culture Collection, Manassas, VA) were cultured 
in DMEM/F12 medium (Lonza, Walkersville, MD) with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Lonza, Hopkington, MA), and 100 U/ml 
penicillin-100 µg/ml streptomycin (Lonza, Hopkington, MA) in a humidified incubator at 37°C, 
10% CO2 and passaged at a ratio of 1:2 to 1:4 using 0.25% Trypsin-EDTA (Invitrogen).   
 
Phalloidin staining of ARPE-19 cells  
ARPE-19 cells were seeded on coverslips placed in a sterile 12-well plate. Cells were 
serum-starved overnight then treated with 20 µM tamoxifen or control media without serum. The 
cells were fixed at 15, 30, 45, 60, 90, 120 and 180 minutes using 3% paraformaldehyde, 
permeabilized using 0.1% Triton X-100, and blocked for 60 minutes by washing with PBS 
between steps.  The cells were then incubated with Alexa Fluor 594 phalloidin (1:100) in 
blocking buffer for 20 minutes, washed, and the coverslips mounted using mounting media with 
DAPI (Prolong Gold Antifade Reagent with DAPI, Life Technologies). Images were taken using 
a Leica AF6000 microscope. 
 
Acridine orange staining of RPE lysosomes 
ARPE-19 cells were seeded in a 48-well plate with complete growth media at a density 
of 3.3 x 104 cells/ well. Cells were grown to confluence and serum-starved overnight before the 
experiment. The following day, cells were incubated with serum-free medium containing 5 µM 
Acridine Orange (Immunochemistry Technologies, Bloomington MN) for 30 minutes at 370 C. 
Cells were washed twice with PBS followed by treatment with 20 µM tamoxifen or control buffer 
for 120 minutes. Images of wells were taken over the course of 2 hours to evaluate the 
progression of lysosomal destabilization with time. 
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Priming of ARPE-19 Cells with IL-1α and quantification of IL-1β secretion and cytotoxicity 
 ARPE-19 cells were seeded onto 12-well plates at a density of 1.0 x 105 cells/well in 
complete growth media.  At confluence, cells were then changed to serum-free medium and 
pre-treated with 10 ng/ml IL-1α for 48 hours. Cells were then treated with 30 µM tamoxifen and 
control buffer in the presence or absence of 30 µM necrostatin and 10 µM Z-YVAD-FMK for 2 
hours. IL-1β was quantified via ELISA (BD Biosciences) as described below. Cytotoxicity was 
assessed by measuring lactate dehydrogenase (LDH) in conditioned media, using the CytoTox 
96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI) as described below. Each 
experimental condition was assayed in triplicate in at least three independent experiments.  
 
Quantification of IL-1β 
ARPE-19 cells were seeded onto 12-well plates in complete media and grown to 
confluence. The cells were primed for 48 hours with 10 ng/mL IL-1α. After 48 hours, the cells 
were treated with tamoxifen (30 µM), DMSO vehicle or 1 mM L-leucyl-L-leucine methyl ester 
(Leu-Leu-OMe; Chem-Impex International, Wood Dale, IL). Conditioned media were collected 
after three hours and IL-1β was quantified via ELISA (BD Biosciences). Values were corrected 
for release of pro-IL-1β due to cytotoxicity using the method described by Miao and colleagues, 
in which levels of lactate dehydrogenase (LDH) in conditioned media were measured using the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI).24 
 
Assessment of cytotoxicity 
The condition media were collected from the treated wells and percent cell death was 
quantified measuring the lactate dehydrogenase in the condition media using the CytoTox 96 
Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI). Condition media from the wells 
treated with control conditions were used as negative control. Percent LDH release was 
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calculated as 100% x (experimental LDH- spontaneous LDH)/ (maximal LDH- spontaneous 
LDH). The LDH levels in wells completely lysed by two freeze-thaw cycles represented 
maximum LDH.  
 
Fluorescent detection of active caspase-1, 3, 8, and 9 
ARPE-19 cells were seeded on to coverslips in complete growth medium and grown to 
confluence. The media were changed to serum-free and the cells incubated overnight. The cells 
were pretreated with FLICA for two hours (protected from light then incubated with tamoxifen 
(20 µM) or an equal volume of DMSO for controls at 37°C, 10% CO2 for 60, 90, and 120 
minutes). The fluorochrome-labeled inhibitor of caspases (FLICA) probes specific for caspase-1, 
3, 8, and 9 (FAM-YVAD-FMK, FAM-DEVD-FMK, FAM-LETD-FMK, and FAM-LEHD-FMK; 
Immunohistochemistry Technologies, Bloomington, MN) were added to each well at the 
concentration recommended by the manufacturer. Following incubation for 60, 90, and 120 
minutes, cells were washed and the cell nuclei were stained with Hoechst 33342 
(Immunohistochemistry Technologies). Cells were then washed and fixed using wash buffer and 
fixative supplied in the FLICA kit, and imaged using a Leica AF6000 microscope.   
 
Western blotting of RIP kinases in ARPE-19 cells 
ARPE-19 cells were lysed using 1X RIPA buffer (Cell Signaling, Boston, MA) containing 
Complete Mini EDTA-free Protease Inhibitor Tablet (Roche, Indianapolis, IN), 2 mM phenyl 
methanesulfonyl fluoride (PMSF), and 2 mM sodium orthovanadate (NaOV) and then sonicated 
on ice. Protein concentrations were measured using BCA assay (ThermoScientific, Waltham, 
MA).  Equal concentrations of protein were separated using 10% polyacrylamide gels and 
transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). Membranes were 
blocked for one hour at room temperature in 3% bovine serum albumin (BSA). The membrane 
was then incubated with anti-RIP3 primary antibody (Abcam) (1:1000 in 1% BSA) overnight at 
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4°C. After three 10-minute washes in Tris-buffered saline with 0.1% Tween 20 (TBS-T), 
membranes were incubated for one hour at room temperature in secondary antibody (1:10,000 
in blocking buffer).  HRP-linked secondary antibodies included anti-mouse IgG (GE Healthcare, 
Pittsburgh, PA) and anti-rabbit IgG (GE Healthcare). Following three more washes in TBS-T, 
proteins were visualized by enhanced chemiluminescence using SuperSignal substrates 
(Thermo Scientific). Membranes were stripped by incubation in Stripping buffer (1 M Tris-HCl, 
pH 6.8; 10% (w/v) SDS; 0.7% beta-mercaptoethanol) for 25 minutes at 55°C to 60°C, re-blocked 
at room temperature in 3% BSA in TBS-T and re-probed with rabbit anti-RIP1.  
 
Statistical Analysis 
 Data are presented as mean ± SEM of at least three independent experiments.  
Statistical significance was evaluated using a one-way analysis of variance followed by post-hoc 
Tukey-Kramer multiple comparison tests, using the Prism 6.0 software package (Graphpad).  
Adjusted P-values < 0.05 were considered statistically significant. 
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RESULTS 
Tamoxifen induces cell death and lysosomal destabilization 
 Treatment of ARPE-19 cells with tamoxifen for two hours at various concentrations (10-
30 µM) induced cell death in a dose-dependent fashion, as detected by release of LDH (Figure 
1A). Two-hour exposure of cells to 10 and 15 µM tamoxifen had little effect on cell viability 
whereas exposure of the ARPE-19 cells for 20, 25 and 30 µM tamoxifen induced 40-70% LDH 
release. Treated cells exhibited features of cell death including swollen cell bodies, shrinkage, 
blebbing, and detachment from the culture substrate (Figure 1B).  Visualization of the 
cytoskeleton by phalloidin staining displayed a loss of actin stress fibers by 60 minutes (Figure 
1C). The active metabolite of tamoxifen, 4-OH-tamoxifen, similarly induced LDH release and cell 
death in ARPE-19 cells in a dose dependent manner (data not shown).  All subsequent studies 
in this report utilized 20 µM tamoxifen unless stated otherwise.    
 Lysosomal integrity was assessed by acridine orange staining, which labels nucleic 
acids green and lysosomes red.  Untreated ARPE-19 cells displayed punctate red-orange 
structures, characteristic of intact lysosomes (Figure 2).  Treatment with tamoxifen resulted in 
loss of lysosomal staining after 20 minutes, indicative of lysosomal destabilization.  Lysosomal 
destabilization occurred prior to LDH release (cell death), suggesting that lysosomal 
destabilization is upstream of tamoxifen-mediated cytotoxicity in these cells. 
 
Lysosomal cathepsins in tamoxifen cytotoxicity 
 Lysosomal membrane permeabilization results in the release of cathepsins, which have 
been implicated in the activation of the NLRP3 inflammasome as well as in the initiation of 
apoptosis and necroptosis.   Blockade of the lysosomal cathepsins B and L with the cathepsin 
B/L inhibitor Z-FF-FMK 25 led to a significant decrease in cell death as measured by LDH 
release (6 ± 2% compared to 73 ± 10% with tamoxifen treatment alone) (Figure 3A). There was 
no statistically significant difference between cathepsin B/L inhibition and concurrent inhibition of 
	  131	  
caspases and RIP1 kinase. The decrease in cell death resulting from the inhibition of the 
cathepsins was greater than any other inhibitor alone, suggesting that cathepsin release from 
lysosomes occurs upstream and prior to the initiation of cell death pathways. 
 To elucidate the role of cathepsin B versus cathepsin L, specific cathepsin B and L 
inhibitors, using the cathepsin B inhibitor CA-074-Me and cathepsin L inhibitor Z-FY(t-Bu)-DMK 
were used (Figure 3C).  Whereas blocking either cathepsin (B or L) protected the cells from 
tamoxifen toxicity, treatment with the cathepsin L inhibitor led to a significantly greater inhibition 
of cell death than the cathepsin B inhibitor (25 ± 6% versus 40 ± 0.4% LDH release).  These 
data suggest a greater role for cathepsin L than cathepsin B in mediating tamoxifen cytotoxicity, 
suggesting that these cell death pathways depend upon the activity of cathepsin L.  As 
expected, concurrent inhibition with the individual cathepsin B and L inhibitors resulted in near 
complete inhibition of cell death (Figure 3C). 
 
Caspases and RIP1 kinase in tamoxifen cytotoxicity  
We have previously shown that ARPE-19 cells express components of the NLRP3 
inflammasome and activate caspase-1 upon lysosomal destabilization. 9 In addition, caspase-1 
is the effector caspase in a form of programmed cell death referred to as pyroptosis.26 The role 
of caspase-1 in tamoxifen toxicity of ARPE-19 cells was investigated using the caspase-1-
specific inhibitor Z-YVAD-FMK.  Two hours of treatment with 20 µM tamoxifen resulted in 73 ± 
10% LDH release; the application of the caspase-1 inhibitor led to a significant decrease in cell 
death (51 ± 5%) (Figure 3A). Pan-caspase inhibition with Z-VAD-FMK did not yield additional 
protection from cell toxicity over that seen with caspases-1 inhibition alone.   
 Nec-1, a potent and selective inhibitor of programmed cell necrosis, targets the activity 
of receptor-interacting protein 1 (RIP1) kinase 17. Concurrent treatment with pan-caspase, 
caspase-1, caspase-3 inhibitors and Nec-1 resulted in near complete inhibition of cell death 
after two hours of treatment with tamoxifen (Figure 3A, B).  Activation of caspase 1 and 3 by 
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tamoxifen was further verified by FLICA assay (Figure 4, rows 1 and 2).  These results implicate 
the activation of multiple caspase and non-caspase dependent cell death pathways with 
application of tamoxifen.     
 In order to investigate the possible involvement of the RIP kinase pathway in ARPE-19 
cells, the expression of RIP1 and RIP3 kinase, the primary mediators of necroptosis were 
examined in ARPE-19 cells. Western blot analysis revealed the expression of both RIP1 and 
RIP3 in ARPE-19 cells (supplemental Figure 1). 
 
Apoptosis occurs primarily through a caspase-9 dependent mechanism 
Apoptosis, a form of cell death that eliminates damaged cells in a controlled manner, is 
characterized by caspase activation, chromatin condensation, nuclear fragmentation, and the 
formation of apoptotic bodies that are phagocytized by surrounding cells in order to prevent 
inflammation.  Two main pathways that are involved in apoptosis, the extrinsic death receptor 
mediated pathway and the intrinsic or mitochondrial pathway, both converge on common 
executioner caspases (caspases-3, -6, and -7); we therefore investigated the relative role of the 
intrinsic and extrinsic pathways of apoptosis.  The extrinsic pathway depends upon activation of 
the initiator caspase-8, which was probed with the caspase-8 specific inhibitor Z-LETD-FMK.  
The intrinsic or mitochondrial pathway of apoptosis was examined using the caspase-9 specific 
inhibitor Z-LEHD-FMK.   
Inhibition of caspase-8 alone did not significantly decrease cell death in cells treated with 
tamoxifen, whereas caspase-9 inhibition alone led to a statistically significant decrease in cell 
death, indicating that apoptosis primarily occurs through the intrinsic pathway and is dependent 
upon mitochondrial dysfunction.  Co-treatment with Nec-1 and caspase-8 inhibition yielded a 
near complete inhibition of cell death, implying that caspase-8 is activated by tamoxifen and that 
its inhibition results in cell death due to the activation of the RIP kinase pathway.  Activation of 
both caspase 8 and 9 was verified with FLICA assay (Figure 4, row 3 and 4). 
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Caspase-1 activation leads to production of IL-1β 
 Lysosomal destabilization has been previously shown to induce the formation of the 
NLRP3 inflammasome and activation of caspase-1 with subsequent release of mature IL-1β and 
pyroptosis.  In order to evaluate the activation of the NLRP3 inflammasome and caspase-1 
activation, we examined mature IL-1β production in ARPE-19 cells treated with tamoxifen.  
ARPE-19 cells were primed with IL-1α for 24 hours and the level of mature IL-1β in the 
conditioned media was quantified by ELISA as previously described.9 
 Tamoxifen-treated ARPE-19 cells produced 17.55 pg/ml of IL-1β.  Inclusion of Nec-1 did 
not reduce IL-1ß levels (15.26 pg/ml) (Figure 5).  In contrast, treatment with the caspase-1 
inhibitor Z-YVAD-FMK led to a significant decrease in the production of IL-1β, which was not 
further decreased by the addition of Nec-1 (6.38 and 7.75 pg/ml respectively) (Figure 5).  These 
results are consistent with NLRP3 inflammasome activation by tamoxifen.  Unprimed ARPE-19 
cells exposed to tamoxifen did not produce mature IL-1β, but did exhibit cell death (data not 
shown), indicating that cell death associated with caspase-1 activity is independent of its ability 
to produce mature IL-1β. 
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DISCUSSION 
 Tamoxifen toxicity of the retina is believed to be mediated by damage to the RPE  
through disruption of lysosomes.3 We examined the mechanisms of tamoxifen toxicity in ARPE-
19 cells and demonstrated that tamoxifen-induced lysosomal destabilization is associated with 
the activation of a number of cell death pathways. We observed lysosomal destabilization in 
ARPE-19 cells within 20 minutes of tamoxifen treatment, a time prior to cell death.  We found 
that cathepsins released upon lysosomal destabilization play a role in initiating multiple cell 
death mechanisms: necroptosis, apoptosis, and pyroptosis. 
Lysosomal membrane permeabilization has been demonstrated to release hydrolases 
such as the cathepsins that have been demonstrated to participate in apoptosis.  Upon their 
release into the cytosol, cathepsins cleave the pro-apoptotic Bcl-2 family member Bid, resulting 
in its activation, and degrade anti-apoptotic protein Bcl-2 proteins, triggering the intrinsic 
pathway of apoptosis. 27 28 Similarly, inhibition of lysosomal cathepsins has been demonstrated 
to block NLRP3 signaling and caspase-1 activation. 5 29 30 In particular, cathepsin B inhibition 
has been implicated in caspase-independent cell death, and cathepsins B and L have been 
found to mediate inflammasome activity in myeloid-derived cells and ARPE-19 cells. Cathepsins 
have also been shown to play a role in necroptosis, specifically, in caspase-compromised 
conditions; necroptosis can be arrested with application of cathepsin B inhibitor CA-074-OMe.31 
Similarly, we have shown that combined cathepsin B and L inhibition leads to complete 
inhibition of cell death, and that the cathepsin release occurs upstream of multiple cell death 
mechanisms. 
Caspases mediate both the extrinsic and intrinsic pathways of apoptosis.  The extrinsic 
apoptosis pathway is activated when death receptor ligands such as TNF-α bind their receptor, 
which  then recruits FADD.  This interaction forms a death-inducing complex, which recruits the 
initiator procaspase-8, leading to its cleavage and activation.  Activated caspase-8 then 
activates caspase-3 and other effector caspases that mediate the cell death pathway. The 
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intrinsic pathway is induced at the level of the mitochondria by cellular stresses (such as DNA 
damage, oxidative stress, or endoplasmic reticulum stress). The initiator procaspase-9 forms a 
complex with the mitochondrial protein cytochrome and apoptotic protease-activating factor 
(APAF-1) to form the apoptosome. 32 Active caspase-9 cleaves and activates effector caspase-
3.  
We demonstrated a significant role for the executioner caspase-3 in tamoxifen 
cytotoxicity.  Further, we have shown a primary role for the caspase-9 dependent intrinsic 
pathway, an observation that is indicative of mitochondrial dysfunction.  This is in agreement 
with the finding that necroptosis induces mitochondrial dysfunction, ROS formation, and release 
of pro-apoptotic proteins of the Bcl-2 family. 33 Although the extrinsic pathway, which is 
caspase-8 dependent, does not seem to play a primary role in tamoxifen-mediated toxicity, 
others have reported that inhibition of caspase-8 activates RIP1 kinase.34 Consistent with this 
finding, co-treatment with Nec-1 and a caspase-8 inhibitor led to near complete inhibition of cell 
death, greater than Nec-1 alone. 
 Necroptosis depends on the activity of the serine/threonine kinase RIP1, an adaptor 
kinase that functions downstream of death domain receptors and forms a complex with RIP3 to 
activate necroptosis.  Exposure of RPE cells to tamoxifen led to the activation of RIP1 and the 
initiation of necroptosis.  As previously demonstrated in photoreceptors in a model of retinal 
detachment, co-treatment with caspase inhibitors and Nec-1 effectively suppresses tamoxifen 
mediated cell death of the RPE.12, 15, 20, 35, 36   
 Pathological activation of the NLRP3 inflammasome is characteristic of a variety of 
disease conditions in which lysosomal destabilization results from phagocytosis of crystals or 
insoluble aggregates.6, 7 For instance, silicosis and asbestosis are mediated by NLRP3 
inflammasome activation in myeloid cells induced by silica crystals and asbestos fibers. 
Similarly, monosodium urate crystals cause gout via NLRP3 activation, and cholesterol crystals 
trigger NLRP3 during the development of atherosclerosis. 4 The NLRP3 inflammasome has 
	  136	  
been detected in RPE of eyes from patients with geographic atrophy and age-related macular 
degeneration 9, and has been postulated to play a role in their pathogenesis.  Similarly, 
tamoxifen retinopathy is associated with the presence of retinal crystalline deposits and displays 
features similar to geographic atrophy with loss of the RPE and subsequent associated retinal 
atrophy. 
The role of the NLRP3 inflammasome in tamoxifen toxicity of ARPE-19 cells is 
evidenced by the rapid activation of caspase-1 with subsequent production of mature IL-1β and 
pyroptosis following tamoxifen treatment.  Caspase-1 contributes to cell death through induction 
of pyroptosis; however, inhibition of caspase-1 significantly but only partially, reduced cell death, 
indicating that while caspase-1 did contribute to tamoxifen-mediated RPE cell death, cell death 
was not mediated predominantly by pyroptosis.  Thus, multiple cell death mechanisms 
contribute to tamoxifen toxicity of the RPE. 
For therapeutic intervention, however, simultaneous inhibition of multiple cell death 
pathways may not be practical. Instead, targeting a common factor upstream of all pathways 
involved would likely yield better outcomes with regard to safety and efficacy. As we have found 
that cathepsins B and L are key mediators of tamoxifen-induced RPE cytotoxicity, these 
proteases may be viable candidates for the development of pharmacological inhibitors. While 
inhibition of only one of these enzymes results in partial reduction of tamoxifen toxicity, blockade 
of both cathepsins completely protects RPE cells from tamoxifen-induced cell death in vitro, and 
this was achieved using a single peptide-derived inhibitor. This overlap in substrate specificity 
may allow for tamoxifen retinopathy to be treated or prevented by a single drug targeting both 
cathepsins B and L.  
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FIGURES 
 
Figure 1.  Tamoxifen cytotoxicity of ARPE-19 cells.  (A) Increasing doses of tamoxifen led to 
ARPE-19 cell death and LDH release.  (B) Bright field microscopy of control and tamoxifen- (20 
µM) treated ARPE-19 cells after 2 hours of exposure.  Cells appeared round and shrunken, and 
were detaching from the tissue culture plate (scale bar = 200 µm).  (C) Phalloidin staining of 
actin fibers (red) and DAPI staining of cell nuclei (blue) reveals progressive loss of stress fibers, 
through time in ARPE-19 cells treated with tamoxifen (scale bar = 25 µm). 
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Figure 2.  Tamoxifen-induced lysosomal destabilization in ARPE-19 cells.  ARPE-19 cells 
were stained acridine orange prior to exposure to 20 µM tamoxifen.  Fluorescence microscopy 
revealed lysosomes (red) and DNA or RNA (green).  Lysosomal destabilization was evident 
within 20 minutes of tamoxifen exposure (scale bar = 10 µm). 
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Figure 3. Pathways of tamoxifen-mediated ARPE-19 cell death.  (A) ARPE-19 cells were 
treated with 20 µM tamoxifen for 2 hours, then treated with Nec-1 (20 µM) plus Z-VAD-FMK, a 
pan-caspase inhibitor (10 µM); Z-YVAD-FMK, a caspase-1 inhibitor (10 µM);  Z-DEVD-FMK,  a 
caspase-3 inhibitor (10 µM); Z-FF-FMK, a cathepsin B/L inhibitor (20 µM) alone or in the 
indicated combinations. (B) Brightfield images of ARPE-19 cells treated as in (A). Upper row 
represents cells treated with individual inhibitors without Nec-1.  Cells were rounded, shrunken 
and were detaching from the substrate.  Treatment with Nec-1 alone inhibited cell death, but the 
cells still appear distressed (bottom row, first panel).  Simultaneous treatment with a pan-
caspase inhibitor and Nec-1 or a caspase-1 inhibitor and necrostatin-1 resulted in near 
complete inhibition of cell death (bottom row, second and third panel). (C) ARPE-19 cells were 
treated with 20 µM tamoxifen for 2 hours, then treated with cathepsin B/L (Z-FF-FMK, 20 µM), 
specific cathepsin B (CA-074-Me) and cathepsin L (Z-FY(t-Bu)-DMK) inhibitors (20 uM) alone or 
in combination.  (D) ARPE-19 cells were treated with 20 µM tamoxifen for 2 hours, then treated 
with Nec-1 (20 µM) plus Z-LETD-FMK, a caspase-8 inhibitor (10 µM); Z-LEHD-FMK, a caspase-
9 inhibitor alone or in combination.  Adjusted P-value ** < 0.05, *** < 0.005, **** < 0.0001 
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Figure 4. Caspase activation in tamoxifen-treated ARPE-19 cells. Fluorochrome-labeled 
inhibitors of caspases (FLICA) were used to examine the activity of caspases-1, -3, -8, and -9 in 
ARPE-19 cells treated with tamoxifen.  (Row 1) Caspase-1 activity was noted 60 minutes after 
exposure to tamoxifen and was increased at 90 and 120 minutes.  (Row 2) Elevated levels of 
caspase-3 activity were measured 90 minutes after application of tamoxifen. (Row 3,4) 
Caspase-8 and caspase-9 activity was observed 60 minutes after application of tamoxifen with 
increasing levels of fluorescence at 90 and 120 minutes.(scale bar = 25 µm). 
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Figure 5.  IL-1β production in primed ARPE-19 cells treated with tamoxifen.  Primed 
ARPE-19 cells produced mature IL-1β when treated with tamoxifen, which was not affected by 
the addition of Nec-1.  Treatment with a caspase-1 specific inhibitor significantly decreased 
production of IL-1β, which was not affected by the addition of Nec-1.  Adjusted P-value ** < 
0.05, *** < 0.005.  
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Supplemental Figure 1.  RIP1 and RIP3 expression in ARPE-19 cells.  RIP1 and RIP3 
expression in ARPE-19 cells treated with tamoxifen 0, 10, 15, 30, 45, and 60 minutes after 
application of tamoxifen.  Protein expression of RIP1 and RIP3 decreases after 45 minutes of 
exposure to tamoxifen. 
